CD4	B-DNA
promoter	I-DNA
transactivation	O
by	O
human	O
herpesvirus	O
6	O
.	O

The	O
observation	O
that	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
induce	O
CD4	B-DNA
gene	I-DNA
transcription	O
and	O
expression	O
in	O
CD4	B-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
cells	I-cell_line
was	O
reported	O
several	O
years	O
ago	O
(	O
P.Lusso	O
,	O
A.De	O
Maria	O
,	O
M.Malnati	O
,	O
F.Lori	O
,	O
S.E.DeRocco	O
,	O
M.	O
Baseler	O
,	O
and	O
R.C.Gallo	O
,	O
Nature	O
349	O
:	O
533-535	O
,	O
1991	O
)	O
and	O
subsequently	O
confirmed	O
(	O
P.Lusso	O
,	O
M.S.Malnati	O
,	O
A.Garzino-Demo	O
,	O
R.W.Crowley	O
,	O
E.	O
O.Long	O
,	O
and	O
R.C.Gallo	O
,	O
Nature	O
362	O
:	O
458-462	O
,	O
1993	O
;	O
G.Furlini	O
,	O
M.	O
Vignoli	O
,	O
E.Ramazzotti	O
,	O
M.C.Re	O
,	O
G.Visani	O
,	O
and	O
M.LaPlaca	O
,	O
Blood	O
87	O
:	O
4737-4745	O
,	O
1996	O
)	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
the	O
mechanisms	O
underlying	O
such	O
phenomena	O
.	O

Using	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
driven	O
by	O
the	O
CD4	B-DNA
promoter	I-DNA
,	O
we	O
report	O
that	O
HHV-6	O
can	O
efficiently	O
transactivate	O
such	O
genetic	B-DNA
elements	I-DNA
.	O

Activation	O
of	O
the	O
CD4	B-DNA
promoter	I-DNA
occurs	O
in	O
the	O
presence	O
of	O
the	O
viral	O
DNA	O
polymerase	O
inhibitor	O
phosphonoformic	O
acid	O
,	O
which	O
limits	O
expression	O
to	O
the	O
immediate-early	B-DNA
and	I-DNA
early	I-DNA
classes	I-DNA
of	I-DNA
viral	I-DNA
genes	I-DNA
.	O

Using	O
deletion	O
mutants	O
and	O
specific	O
CD4	B-DNA
promoter	I-DNA
mutants	I-DNA
,	O
we	O
identified	O
an	O
ATF/CRE	B-DNA
binding	I-DNA
site	I-DNA
located	O
at	O
nucleotides	B-DNA
-67	I-DNA
to	I-DNA
-60	I-DNA
upstream	I-DNA
of	O
the	O
CD4	B-DNA
gene	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
that	O
is	O
important	O
for	O
HHV-6	O
transactivation	O
.	O

The	O
ATF/CRE	B-DNA
site	I-DNA
is	O
also	O
essential	O
for	O
CD4	B-DNA
promoter	I-DNA
activation	O
by	O
forskolin	O
,	O
an	O
activator	O
of	O
adenylate	O
cyclase	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
specific	O
antibodies	O
,	O
we	O
showed	O
that	O
CREB-1	B-protein
binds	O
specifically	O
to	O
the	O
-79	B-DNA
to	I-DNA
-52	I-DNA
region	I-DNA
of	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O

Last	O
,	O
we	O
have	O
identified	O
two	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
of	O
HHV-6	O
,	O
U86	B-DNA
and	O
U89	B-DNA
from	O
the	O
immediate-early	O
locus	O
A	O
,	O
that	O
can	O
transactivate	O
the	O
CD4	B-DNA
promoter	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
.	O

However	O
,	O
transactivation	O
of	O
the	O
CD4	B-DNA
promoter	I-DNA
by	O
ORFs	B-DNA
U86	B-DNA
and	O
U89	B-DNA
is	O
independent	O
of	O
the	O
CRE	B-DNA
element	I-DNA
,	O
suggesting	O
that	O
additional	O
HHV-6	B-DNA
ORFs	I-DNA
are	O
likely	O
to	O
contribute	O
to	O
CD4	B-DNA
gene	I-DNA
activation	O
.	O

Taken	O
together	O
,	O
our	O
results	O
will	O
help	O
to	O
understand	O
the	O
complex	O
interactions	O
occurring	O
between	O
HHV-6	O
and	O
the	O
CD4	B-DNA
promoter	I-DNA
and	O
provide	O
additional	O
information	O
regarding	O
the	O
class	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
control	O
of	O
CD4	B-DNA
gene	I-DNA
expression	O
.	O

JOURNAL	NULL
OF	NULL
ViROLOGY	NULL
,	NULL
Nov.	NULL
1998	NULL
,	NULL
p.	NULL
8797-8805	NULL
0022-538	NULL
X	NULL
,	NULL
/98/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

72	NULL
,	NULL
No	NULL
.	NULL

11	NULL
Copyright	NULL
©	NULL
1998	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

CD4	NULL
Promoter	NULL
Transactivation	NULL
by	NULL
Human	NULL
Herpesvirus	NULL
6	NULL
LOUIS	NULL
FLAMAND	NULL
,	NULL
*'*	NULL
FABIO	NULL
ROMERIO	NULL
,	NULL
*	NULL
MARVIN	NULL
S.	NULL
REITZ	NULL
,	NULL
*	NULL
anp	NULL
ROBERT	NULL
C.	NULL
GALLO	NULL
Laboratory	NULL
of	NULL
Virology	NULL
,	NULL
Rheumatology	NULL
and	NULL
Immunology	NULL
Research	NULL
Center	NULL
,	NULL
Centre	NULL
de	NULL
Recherche	NULL
du	NULL
CHUL	NULL
and	NULL
Laval	NULL
University	NULL
,	NULL
Sainte-Foy	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
,	NULL
``	NULL
and	NULL
Institute	NULL
of	NULL
Human	NULL
Virology	NULL
,	NULL
University	NULL
of	NULL
Maryland	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
212012	NULL
Received	NULL
26	NULL
February	NULL
1998/Accepted	NULL
4	NULL
August	NULL
1998	NULL
The	NULL
observation	NULL
that	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
can	NULL
induce	NULL
CD4	NULL
gene	NULL
transcription	NULL
and	NULL
expression	NULL
in	NULL
CD4~	NULL
cells	NULL
was	NULL
reported	NULL
several	NULL
years	NULL
ago	NULL
(	NULL
P.	NULL
Lusso	NULL
,	NULL
A	NULL
.	NULL

De	NULL
Maria	NULL
,	NULL
M.	NULL
Malnati	NULL
,	NULL
F.	NULL
Lori	NULL
,	NULL
S.	NULL
E.	NULL
DeRocco	NULL
,	NULL
M.	NULL
Baseler	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
Nature	NULL
349:533-535	NULL
,	NULL
1991	NULL
)	NULL
and	NULL
subsequently	NULL
confirmed	NULL
(	NULL
P.	NULL
Lusso	NULL
,	NULL
M.	NULL
S.	NULL
Malnati	NULL
,	NULL
A.	NULL
Garzino-Demo	NULL
,	NULL
R.	NULL
W.	NULL
Crowley	NULL
,	NULL
E.	NULL
O	NULL
.	NULL

Long	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
Nature	NULL
362:458-462	NULL
,	NULL
1993	NULL
;	NULL
G.	NULL
Furlini	NULL
,	NULL
M.	NULL
Vignoli	NULL
,	NULL
E.	NULL
Ramazzotti	NULL
,	NULL
M.	NULL
C.	NULL
Re	NULL
,	NULL
G.	NULL
Visani	NULL
,	NULL
and	NULL
M.	NULL
LaPlaca	NULL
,	NULL
Blood	NULL
87:4737-4745	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Our	NULL
objective	NULL
was	NULL
to	NULL
identify	NULL
the	NULL
mechanisms	NULL
underlying	NULL
such	NULL
phenomena	NULL
.	NULL

Using	NULL
reporter	NULL
gene	NULL
constructs	NULL
driven	NULL
by	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
we	NULL
report	NULL
that	NULL
HHV-6	NULL
can	NULL
efficiently	NULL
transactivate	NULL
such	NULL
genetic	NULL
elements	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
occurs	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
viral	NULL
DNA	NULL
polymerase	NULL
inhibitor	NULL
phosphonoformic	NULL
acid	NULL
,	NULL
which	NULL
limits	NULL
expression	NULL
to	NULL
the	NULL
immediate-early	NULL
and	NULL
early	NULL
classes	NULL
of	NULL
viral	NULL
genes	NULL
.	NULL

Using	NULL
deletion	NULL
mutants	NULL
and	NULL
specific	NULL
CD4	NULL
promoter	NULL
mutants	NULL
,	NULL
we	NULL
identified	NULL
an	NULL
ATF/CRE	NULL
binding	NULL
site	NULL
located	NULL
at	NULL
nucleotides	NULL
-67	NULL
to	NULL
-60	NULL
upstream	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
transcription	NULL
start	NULL
site	NULL
that	NULL
is	NULL
important	NULL
for	NULL
HHV-6	NULL
transactivation	NULL
.	NULL

The	NULL
ATF/CRE	NULL
site	NULL
is	NULL
also	NULL
essential	NULL
for	NULL
CD4	NULL
promoter	NULL
activation	NULL
by	NULL
forskolin	NULL
,	NULL
an	NULL
activator	NULL
of	NULL
adenylate	NULL
cyclase	NULL
.	NULL

Using	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
and	NULL
specific	NULL
antibodies	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
CREB-1	NULL
binds	NULL
specifically	NULL
to	NULL
the	NULL
-79	NULL
to	NULL
-52	NULL
region	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Last	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
two	NULL
open	NULL
reading	NULL
frames	NULL
(	NULL
ORFs	NULL
)	NULL
of	NULL
HHV-6	NULL
,	NULL
U8S6	NULL
and	NULL
US9	NULL
from	NULL
the	NULL
immediate-early	NULL
locus	NULL
A	NULL
,	NULL
that	NULL
can	NULL
transactivate	NULL
the	NULL
CD4	NULL
promoter	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
transactivation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
ORFs	NULL
U86	NULL
and	NULL
U89	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
CRE	NULL
element	NULL
,	NULL
suggesting	NULL
that	NULL
additional	NULL
HHV-6	NULL
ORFs	NULL
are	NULL
likely	NULL
to	NULL
contribute	NULL
to	NULL
CD4	NULL
gene	NULL
activation	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
will	NULL
help	NULL
to	NULL
understand	NULL
the	NULL
complex	NULL
interactions	NULL
occurring	NULL
between	NULL
HHV-6	NULL
and	NULL
the	NULL
CD4	NULL
promoter	NULL
and	NULL
provide	NULL
additional	NULL
information	NULL
regarding	NULL
the	NULL
class	NULL
of	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
CD4	NULL
gene	NULL
expression	NULL
.	NULL

The	NULL
CD4	NULL
antigen	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
both	NULL
T-cell	NULL
development	NULL
and	NULL
T-cell	NULL
antigen	NULL
recognition	NULL
(	NULL
24	NULL
,	NULL
36	NULL
,	NULL
37	NULL
,	NULL
46	NULL
)	NULL
.	NULL

CD4	NULL
,	NULL
through	NULL
interactions	NULL
with	NULL
the	NULL
nonpolymorphic	NULL
region	NULL
of	NULL
the	NULL
class	NULL
II	NULL
antigen	NULL
of	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
,	NULL
acts	NULL
as	NULL
an	NULL
adhesion	NULL
molecule	NULL
that	NULL
helps	NULL
stabilize	NULL
the	NULL
complex	NULL
formed	NULL
by	NULL
the	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
and	NULL
MHC	NULL
class	NULL
II	NULL
antigen	NULL
(	NULL
5	NULL
,	NULL
7	NULL
,	NULL
13	NULL
,	NULL
21	NULL
)	NULL
.	NULL

CD4	NULL
can	NULL
also	NULL
participate	NULL
in	NULL
T-cell	NULL
activation	NULL
through	NULL
transmembrane	NULL
signaling	NULL
via	NULL
the	NULL
p56	NULL
``	NULL
**	NULL
tyrosine	NULL
kinase	NULL
associated	NULL
with	NULL
its	NULL
cytoplasmic	NULL
tail	NULL
(	NULL
39	NULL
,	NULL
43	NULL
,	NULL
48	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Control	NULL
of	NULL
CD4	NULL
gene	NULL
expression	NULL
is	NULL
very	NULL
complex	NULL
.	NULL

During	NULL
the	NULL
ontogeny	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
CD4	NULL
gene	NULL
expression	NULL
is	NULL
turned	NULL
on	NULL
and	NULL
off	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
stage	NULL
of	NULL
maturation	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
.	NULL

A	NULL
series	NULL
of	NULL
genetic	NULL
elements	NULL
,	NULL
including	NULL
the	NULL
enhancer	NULL
(	NULL
4	NULL
,	NULL
41	NULL
,	NULL
45	NULL
,	NULL
52	NULL
)	NULL
,	NULL
promoter	NULL
(	NULL
40	NULL
)	NULL
,	NULL
and	NULL
silencer	NULL
(	NULL
6	NULL
,	NULL
42	NULL
,	NULL
44	NULL
)	NULL
,	NULL
are	NULL
involved	NULL
in	NULL
control	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
these	NULL
genetic	NULL
elements	NULL
for	NULL
proper	NULL
CD4	NULL
expression	NULL
was	NULL
demonstrated	NULL
using	NULL
transgenic	NULL
animal	NULL
models	NULL
(	NULL
4	NULL
,	NULL
6	NULL
,	NULL
42	NULL
,	NULL
44	NULL
)	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
all	NULL
regulatory	NULL
sequences	NULL
is	NULL
required	NULL
for	NULL
proper	NULL
tissue	NULL
expression	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
.	NULL

Removal	NULL
of	NULL
any	NULL
one	NULL
of	NULL
these	NULL
elements	NULL
influences	NULL
either	NULL
the	NULL
level	NULL
of	NULL
expression	NULL
or	NULL
the	NULL
cell	NULL
type	NULL
in	NULL
which	NULL
the	NULL
gene	NULL
is	NULL
expressed	NULL
.	NULL

Maturation	NULL
of	NULL
double-positive	NULL
CD4	NULL
~CD8*	NULL
thymic	NULL
cells	NULL
into	NULL
mature	NULL
single-positive	NULL
CD4*CD8~	NULL
or	NULL
CD4~-CD8*	NULL
peripheral	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
consequence	NULL
of	NULL
selective	NULL
downregulation	NULL
of	NULL
the	NULL
CD8	NULL
or	NULL
the	NULL
CD4	NULL
gene	NULL
,	NULL
respectively	NULL
.	NULL

Inhibition	NULL
of	NULL
CD4	NULL
gene	NULL
expression	NULL
in	NULL
mature	NULL
CD8	NULL
T	NULL
cells	NULL
occurs	NULL
at	NULL
the	NULL
transcription	NULL
level	NULL
through	NULL
the	NULL
action	NULL
of	NULL
the	NULL
CD4	NULL
silencer	NULL
(	NULL
42	NULL
,	NULL
44	NULL
)	NULL
.	NULL

*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Centre	NULL
de	NULL
Recherche	NULL
du	NULL
CHUL	NULL
,	NULL
Rheumatology	NULL
and	NULL
Immunology	NULL
Dept	NULL
.	NULL

,	NULL
Room	NULL
T1-49	NULL
,	NULL
2705	NULL
Laurier	NULL
Blvd	NULL
.	NULL

,	NULL
Sainte-Foy	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
G1V	NULL
4G2	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
418	NULL
)	NULL
654-2772	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
418	NULL
)	NULL
654-2765	NULL
.	NULL

E-mail	NULL
:	NULL
louis	NULL
flamand	NULL
@	NULL
crchul.ulaval	NULL
.ca	NULL
.	NULL

8797	NULL
Very	NULL
few	NULL
experimental	NULL
conditions	NULL
were	NULL
found	NULL
to	NULL
influence	NULL
CD4	NULL
gene	NULL
activation	NULL
in	NULL
mature	NULL
CD8*	NULL
T	NULL
cells	NULL
.	NULL

Treatment	NULL
of	NULL
mature	NULL
CD8*	NULL
T	NULL
cells	NULL
with	NULL
azacytidine	NULL
(	NULL
38	NULL
)	NULL
,	NULL
with	NULL
the	NULL
lectin	NULL
concanavalin	NULL
A	NULL
(	NULL
3	NULL
)	NULL
,	NULL
or	NULL
with	NULL
TCR	NULL
agonists	NULL
(	NULL
9	NULL
)	NULL
was	NULL
found	NULL
to	NULL
induce	NULL
cell	NULL
surface	NULL
CD4	NULL
expression	NULL
.	NULL

Infection	NULL
of	NULL
mature	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
was	NULL
also	NULL
found	NULL
to	NULL
induce	NULL
CD4	NULL
expression	NULL
(	NULL
26	NULL
)	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
activate	NULL
the	NULL
CD4	NULL
gene	NULL
was	NULL
also	NULL
demonstrated	NULL
in	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
and	NULL
in	NULL
the	NULL
hematopoietic	NULL
progenitor	NULL
cell	NULL
line	NULL
KG-1	NULL
(	NULL
14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
leading	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
CD4	NULL
were	NULL
never	NULL
studied	NULL
.	NULL

HHV-6	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
play	NULL
a	NULL
cofactorial	NULL
role	NULL
in	NULL
progression	NULL
to	NULL
AIDS	NULL
.	NULL

Several	NULL
observations	NULL
prompted	NULL
this	NULL
hy-pothesis	NULL
.	NULL

(	NULL
i	NULL
)	NULL
HHV-6	NULL
can	NULL
infect	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
25	NULL
,	NULL
27	NULL
,	NULL
29	NULL
,	NULL
47	NULL
)	NULL
and	NULL
therefore	NULL
contribute	NULL
to	NULL
the	NULL
decline	NULL
of	NULL
such	NULL
cell	NULL
popula-tions	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
HHV-6	NULL
can	NULL
transactivate	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
,	NULL
thereby	NULL
increasing	NULL
HIV	NULL
expression	NULL
(	NULL
8	NULL
,	NULL
15	NULL
,	NULL
19	NULL
,	NULL
20	NULL
,	NULL
30	NULL
,	NULL
35	NULL
,	NULL
50	NULL
)	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
HHV-6	NULL
is	NULL
a	NULL
potent	NULL
inducer	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
secretion	NULL
(	NULL
10	NULL
)	NULL
,	NULL
an	NULL
inflammatory	NULL
cytokine	NULL
known	NULL
to	NULL
activate	NULL
HIV	NULL
expression	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
HHV-6	NULL
can	NULL
impair	NULL
immunological	NULL
functions	NULL
such	NULL
as	NULL
T-cell	NULL
proliferation	NULL
(	NULL
11	NULL
,	NULL
18	NULL
)	NULL
and	NULL
interleukin-2	NULL
synthesis	NULL
(	NULL
11	NULL
)	NULL
.	NULL

(	NULL
v	NULL
)	NULL
HHV-6	NULL
can	NULL
induce	NULL
CD4	NULL
expression	NULL
,	NULL
thereby	NULL
expanding	NULL
the	NULL
types	NULL
of	NULL
target	NULL
cells	NULL
susceptible	NULL
to	NULL
HIV	NULL
infection	NULL
(	NULL
14	NULL
,	NULL
26	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
latter	NULL
is	NULL
not	NULL
likely	NULL
to	NULL
significantly	NULL
contribute	NULL
to	NULL
disease	NULL
,	NULL
as	NULL
HHV-6-infected	NULL
cells	NULL
will	NULL
eventually	NULL
die	NULL
,	NULL
the	NULL
mechanisms	NULL
implicated	NULL
in	NULL
CD4	NULL
gene	NULL
activation	NULL
by	NULL
HHV-6	NULL
are	NULL
of	NULL
biological	NULL
interest	NULL
and	NULL
will	NULL
contribute	NULL
to	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
genetic	NULL
control	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
.	NULL

In	NULL
the	NULL
present	NULL
work	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
interactions	NULL
between	NULL
HHV-6	NULL
and	NULL
the	NULL
CD4	NULL
promoter	NULL
and	NULL
have	NULL
identified	NULL
a	NULL
functional	NULL
transcription	NULL
factor	NULL
binding	NULL
site	NULL
belonging	NULL
to	NULL
the	NULL
ATF/	NULL
CRE	NULL
family	NULL
.	NULL

This	NULL
site	NULL
is	NULL
important	NULL
in	NULL
HHV-6-mediated	NULL
trans-	NULL
8798	NULL
FLAMAND	NULL
ET	NULL
AL	NULL
.	NULL

activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Furthermore	NULL
,	NULL
two	NULL
genes	NULL
of	NULL
HHV-6	NULL
(	NULL
U86	NULL
and	NULL
U89	NULL
)	NULL
were	NULL
found	NULL
to	NULL
transactivate	NULL
the	NULL
human	NULL
CD4	NULL
promoter	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
provide	NULL
new	NULL
information	NULL
regarding	NULL
transcription	NULL
factors	NULL
interacting	NULL
with	NULL
the	NULL
CD4	NULL
promoter	NULL
and	NULL
shed	NULL
light	NULL
on	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
HHV-6	NULL
activates	NULL
CD4	NULL
gene	NULL
expression	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cells	NULL
,	NULL
culture	NULL
conditions	NULL
,	NULL
and	NULL
virus	NULL
production	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
NIH	NULL
AIDS	NULL
Research	NULL
and	NULL
Reference	NULL
Reagent	NULL
Program	NULL
,	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Manassas	NULL
,	NULL
Va.	NULL
)	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
obtained	NULL
as	NULL
cultures	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
FBS	NULL
)	NULL
and	NULL
antibiotics	NULL
.	NULL

Cells	NULL
were	NULL
fed	NULL
once	NULL
every	NULL
4	NULL
to	NULL
5	NULL
days	NULL
and	NULL
seeded	NULL
at	NULL
a	NULL
density	NULL
of	NULL
3	NULL
X	NULL
10°	NULL
cells/ml	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
(	NULL
D-MEM	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
and	NULL
antibiotics	NULL
.	NULL

Cells	NULL
were	NULL
passaged	NULL
once	NULL
a	NULL
week	NULL
.	NULL

HHV-6	NULL
(	NULL
GS	NULL
strain	NULL
)	NULL
was	NULL
propagated	NULL
in	NULL
HSB-2	NULL
cells	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Transfection	NULL
and	NULL
infection	NULL
and	NULL
luciferase	NULL
determination	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
12	NULL
)	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
centrifuged	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
multiplicity	NULL
of	NULL
infection	NULL
,	NULL
0.1	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
to	NULL
remove	NULL
unadsorbed	NULL
virions	NULL
and	NULL
resuspended	NULL
in	NULL
complete	NULL
medium	NULL
.	NULL

In	NULL
experiments	NULL
involving	NULL
the	NULL
drug	NULL
phosphonoformic	NULL
acid	NULL
(	NULL
PFA	NULL
)	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
PFA/ml	NULL
prior	NULL
to	NULL
infection	NULL
with	NULL
HHV-6	NULL
and	NULL
kept	NULL
throughout	NULL
the	NULL
experiment	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
lysed	NULL
in	NULL
150	NULL
pl	NULL
of	NULL
cell	NULL
culture	NULL
lysis	NULL
buffer	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
.	NULL

Twenty	NULL
microliters	NULL
of	NULL
extracts	NULL
was	NULL
added	NULL
to	NULL
100	NULL
pl	NULL
of	NULL
luciferase	NULL
assay	NULL
reagents	NULL
(	NULL
Promega	NULL
)	NULL
,	NULL
and	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
a	NULL
T20/20	NULL
luminometer	NULL
(	NULL
Turner	NULL
Design	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

For	NULL
cotransfection	NULL
studies	NULL
,	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
lipofectamine	NULL
reagent	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
plated	NULL
1	NULL
day	NULL
prior	NULL
to	NULL
transfection	NULL
at	NULL
2	NULL
X	NULL
10°/well	NULL
in	NULL
a	NULL
6-well	NULL
plate	NULL
.	NULL

DNA	NULL
(	NULL
0.75	NULL
pg	NULL
of	NULL
reporter	NULL
plasmids	NULL
and	NULL
0.75	NULL
ug	NULL
of	NULL
effector	NULL
plasmids	NULL
)	NULL
was	NULL
mixed	NULL
and	NULL
incubated	NULL
with	NULL
6	NULL
pl	NULL
of	NULL
lipofectamine	NULL
reagent	NULL
before	NULL
being	NULL
added	NULL
to	NULL
HeLa	NULL
cells	NULL
.	NULL

After	NULL
5	NULL
h	NULL
,	NULL
complete	NULL
D-MEM	NULL
was	NULL
added	NULL
to	NULL
the	NULL
wells	NULL
.	NULL

Forty-cight	NULL
hours	NULL
posttransfection	NULL
the	NULL
medium	NULL
was	NULL
removed	NULL
and	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
lysed	NULL
in	NULL
cell	NULL
culture	NULL
lysis	NULL
buffer	NULL
.	NULL

Luciferase	NULL
activity	NULL
in	NULL
cach	NULL
sample	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
above	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
reporter	NULL
plasmids	NULL
and	NULL
were	NULL
treated	NULL
the	NULL
next	NULL
day	NULL
with	NULL
forskolin	NULL
(	NULL
10	NULL
wM	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
or	NULL
the	NULL
control	NULL
diluent	NULL
dimethyl	NULL
sulfoxide	NULL
(	NULL
DMSO	NULL
)	NULL
.	NULL

After	NULL
an	NULL
additional	NULL
24	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Flow	NULL
cytometry	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HHV-6	NULL
until	NULL
signs	NULL
of	NULL
infection	NULL
(	NULL
ballooning	NULL
)	NULL
were	NULL
observed	NULL
(	NULL
4	NULL
to	NULL
7	NULL
days	NULL
)	NULL
by	NULL
photonic	NULL
microscopy	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
containing	NULL
0.1	NULL
%	NULL
FBS	NULL
.	NULL

Phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-labeled	NULL
anti-human	NULL
CD4	NULL
(	NULL
Pharmingen	NULL
)	NULL
or	NULL
PE-labeled	NULL
isotype-matched	NULL
control	NULL
antibodies	NULL
were	NULL
added	NULL
to	NULL
the	NULL
infected	NULL
and	NULL
uninfected	NULL
cells	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
15	NULL
ml	NULL
of	NULL
cold	NULL
PBS	NULL
and	NULL
fixed	NULL
in	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
HHV-6	NULL
infection	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
monoclonal	NULL
antibody	NULL
OHV-1	NULL
against	NULL
gp106	NULL
of	NULL
HHV-6	NULL
(	NULL
Advanced	NULL
Biotechnologies	NULL
Inc.	NULL
,	NULL
Columbia	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

and	NULL
fluores-cein-labeled	NULL
goat	NULL
anti-mouse	NULL
immunoglobulin	NULL
G	NULL
antibodies	NULL
.	NULL

Percentages	NULL
of	NULL
cells	NULL
expressing	NULL
CD4	NULL
and	NULL
HHV-6	NULL
were	NULL
determined	NULL
with	NULL
a	NULL
FACScalibur	NULL
flow	NULL
cytom-eter	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
after	NULL
the	NULL
acquisition	NULL
of	NULL
10,000	NULL
events	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
and	NULL
generation	NULL
of	NULL
reporter	NULL
gene	NULL
constructs	NULL
.	NULL

The	NULL
human	NULL
CD4	NULL
promoter	NULL
was	NULL
cloned	NULL
using	NULL
a	NULL
PCR	NULL
approach	NULL
.	NULL

From	NULL
the	NULL
published	NULL
sequence	NULL
(	NULL
40	NULL
)	NULL
(	NULL
GenBank	NULL
accession	NULL
no	NULL
.	NULL

UO1066	NULL
)	NULL
two	NULL
primers	NULL
were	NULL
synthesized	NULL
(	NULL
sense	NULL
,	NULL
and	NULL
antisense	NULL
,	NULL
5'-TTCCTTCTGCAGAGTCGTGCT-3	NULL
'	NULL
)	NULL
and	NULL
used	NULL
to	NULL
amplify	NULL
an	NULL
1,100-bp	NULL
fragment	NULL
of	NULL
Jurkat	NULL
cell	NULL
genomic	NULL
DNA	NULL
using	NULL
Pfz	NULL
DNA	NULL
polymerase	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

The	NULL
blunt-ended	NULL
PCR	NULL
fragment	NULL
was	NULL
treated	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
Smel	NULL
site	NULL
of	NULL
the	NULL
pGL3basic	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
to	NULL
generate	NULL
the	NULL
-1076CD4p	NULL
construct	NULL
.	NULL

The	NULL
presence	NULL
and	NULL
orientation	NULL
of	NULL
the	NULL
insert	NULL
were	NULL
determined	NULL
by	NULL
restriction	NULL
endonuclease	NULL
digestion	NULL
and	NULL
sequencing	NULL
.	NULL

Generation	NULL
of	NULL
5°	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

To	NULL
generate	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
the	NULL
-1076CD4p	NULL
plasmid	NULL
was	NULL
digested	NULL
with	NULL
Nsil	NULL
and	NULL
KpnI	NULL
and	NULL
electrophoresed	NULL
through	NULL
a	NULL
1	NULL
%	NULL
agarose	NULL
gel	NULL
.	NULL

The	NULL
5.4-kb	NULL
band	NULL
was	NULL
isolated	NULL
using	NULL
a	NULL
QIAEX	NULL
extraction	NULL
kit	NULL
(	NULL
QIAGEN	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
and	NULL
treated	NULL
with	NULL
S1	NULL
nuclease	NULL
to	NULL
remove	NULL
the	NULL
3	NULL
'	NULL
protruding	NULL
ends	NULL
.	NULL

The	NULL
plasmid	NULL
was	NULL
then	NULL
treated	NULL
with	NULL
Klenow	NULL
enzyme	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
Ind	NULL
.	NULL
)	NULL

,	NULL
extracted	NULL
with	NULL
phenol	NULL
,	NULL
precipitated	NULL
,	NULL
and	NULL
ligated	NULL
using	NULL
the	NULL
fast	NULL
ligation	NULL
kit	NULL
from	NULL
Bochringer	NULL
Mannheim	NULL
.	NULL

Ligated	NULL
plasmids	NULL
were	NULL
used	NULL
to	NULL
transformed	NULL
Escherichia	NULL
coli	NULL
DHSa	NULL
cells	NULL
,	NULL
and	NULL
recombinant	NULL
clones	NULL
were	NULL
confirmed	NULL
by	NULL
restriction	NULL
endonuclease	NULL
digestion	NULL
and	NULL
sequencing	NULL
.	NULL

This	NULL
construct	NULL
was	NULL
named	NULL
-618CD4p	NULL
.	NULL

To	NULL
generate	NULL
-333CD4p	NULL
,	NULL
the	NULL
-1076CD4p	NULL
construct	NULL
was	NULL
digested	NULL
with	NULL
Apel	NULL
and	NULL
KpnI	NULL
and	NULL
the	NULL
5.1-kb	NULL
band	NULL
was	NULL
isolated	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
plasmid	NULL
was	NULL
treated	NULL
with	NULL
S1	NULL
nuclease	NULL
,	NULL
Klenow	NULL
enzyme	NULL
,	NULL
and	NULL
self	NULL
ligated	NULL
.	NULL

Bacteria	NULL
were	NULL
transformed	NULL
,	NULL
and	NULL
recombinants	NULL
were	NULL
identified	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
-71CD4p	NULL
construct	NULL
was	NULL
generated	NULL
by	NULL
digesting	NULL
-1076CD4p	NULL
with	NULL
NkeI	NULL
and	NULL
Pvull	NULL
.	NULL

The	NULL
4.9-kb	NULL
band	NULL
was	NULL
isolated	NULL
as	NULL
described	NULL
above	NULL
and	NULL
treated	NULL
with	NULL
Klenow	NULL
enzyme	NULL
to	NULL
generate	NULL
blunt	NULL
ends	NULL
.	NULL

After	NULL
ligation	NULL
,	NULL
bacteria	NULL
were	NULL
transformed	NULL
and	NULL
J.	NULL
ViRoL	NULL
.	NULL

recombinants	NULL
were	NULL
selected	NULL
with	NULL
ampicillin	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

The	NULL
-71CD4p	NULL
mutant	NULL
clone	NULL
was	NULL
identified	NULL
by	NULL
digestion	NULL
and	NULL
sequencing	NULL
.	NULL

The	NULL
-44CD4p	NULL
clone	NULL
was	NULL
generated	NULL
by	NULL
digesting	NULL
-1076CD4p	NULL
with	NULL
Nhe	NULL
!	NULL

and	NULL
BinI	NULL
.	NULL

The	NULL
4.9-kb	NULL
band	NULL
was	NULL
isolated	NULL
by	NULL
gel	NULL
electrophoresis	NULL
,	NULL
treated	NULL
with	NULL
Klenow	NULL
enzyme	NULL
,	NULL
and	NULL
self	NULL
ligated	NULL
.	NULL

Mutant	NULL
clones	NULL
were	NULL
identified	NULL
by	NULL
restriction	NULL
endonuclease	NULL
digestion	NULL
and	NULL
sequencing	NULL
.	NULL

Internal	NULL
deletion	NULL
mutant	NULL
and	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

To	NULL
generate	NULL
the	NULL
A-71-44CD4p	NULL
mutant	NULL
,	NULL
the	NULL
-1076CD4p	NULL
construct	NULL
was	NULL
digested	NULL
with	NULL
Pvull	NULL
and	NULL
BinL	NULL
.	NULL

The	NULL
5.9-kb	NULL
band	NULL
was	NULL
purified	NULL
by	NULL
gel	NULL
electrophoresis	NULL
,	NULL
treated	NULL
with	NULL
Klenow	NULL
,	NULL
and	NULL
self	NULL
ligated	NULL
.	NULL

After	NULL
bacterial	NULL
transformation	NULL
,	NULL
clones	NULL
were	NULL
isolated	NULL
and	NULL
the	NULL
internal	NULL
deletion	NULL
mutant	NULL
was	NULL
identified	NULL
by	NULL
restriction	NULL
endonuclease	NULL
digestion	NULL
and	NULL
sequencing	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
putative	NULL
ATF/CRE	NULL
site	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
Chameleon	NULL
mutagenesis	NULL
kit	NULL
,	NULL
following	NULL
the	NULL
manufacturer	NULL
's	NULL
technical	NULL
guidelines	NULL
(	NULL
Stratagene	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
-1076CD4p	NULL
and	NULL
the	NULL
-71CD4p	NULL
constructs	NULL
were	NULL
mutated	NULL
to	NULL
generate	NULL
-1076M5CD4p	NULL
and	NULL
-71M5CD4p	NULL
.	NULL

The	NULL
mutation	NULL
changed	NULL
the	NULL
ATF/CRE	NULL
site	NULL
(	NULL
TGACGT	NULL
)	NULL
to	NULL
a	NULL
Drel	NULL
site	NULL
(	NULL
TTTAAA	NULL
)	NULL
.	NULL

Mutation	NULL
was	NULL
confirmed	NULL
by	NULL
digestion	NULL
with	NULL
DreI	NULL
and	NULL
sequencing	NULL
of	NULL
the	NULL
region	NULL
of	NULL
interest	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
uninfected	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
5a	NULL
)	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
used	NULL
for	NULL
CD4-CRE	NULL
binding	NULL
studies	NULL
were	NULL
:	NULL
(	NULL
sense	NULL
)	NULL
5'-AGCTCCAGCTGGTGACGTTITGGGGCCG	NULL
G-3	NULL
'	NULL
and	NULL
(	NULL
antisense	NULL
)	NULL
5'-CCGGCCCCAAACGTCACCAGCTGGAGCT-3	NULL
'	NULL
,	NULL
which	NULL
correspond	NULL
to	NULL
the	NULL
-79	NULL
to	NULL
-52	NULL
region	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

The	NULL
double-stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
consensus	NULL
CRE	NULL
binding	NULL
site	NULL
(	NULL
sense	NULL
,	NULL
5-AGAGATTGCCTGACGTCAGAGAGCTAG-3	NULL
'	NULL
)	NULL
and	NULL
the	NULL
mutant	NULL
CRE	NULL
binding	NULL
site	NULL
(	NULL
sense	NULL
,	NULL
5-AGAGATTGCCTGTGGTCAGAGAGCTAG-3	NULL
'	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

One	NULL
hundred	NULL
nanograms	NULL
of	NULL
the	NULL
CD4-CRE	NULL
probe	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
P	NULL
]	NULL
ATP	NULL
using	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

and	NULL
purified	NULL
over	NULL
a	NULL
spin	NULL
column	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
.	NULL

Gel	NULL
shift	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
as	NULL
follows	NULL
:	NULL
8	NULL
g	NULL
of	NULL
nuclear	NULL
extracts	NULL
was	NULL
preincubated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
in	NULL
a	NULL
binding	NULL
buffer	NULL
containing	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
2.5	NULL
mM	NULL
EDTA	NULL
,	NULL
2.5	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
250	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
50	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
.	NULL

Subsequently	NULL
,	NULL
0.1	NULL
ng	NULL
(	NULL
5	NULL
X	NULL
10	NULL
%	NULL
cpm	NULL
)	NULL
of	NULL
the	NULL
labeled	NULL
probe	NULL
was	NULL
added	NULL
to	NULL
the	NULL
mixture	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
resolved	NULL
on	NULL
a	NULL
4	NULL
%	NULL
nondenaturing	NULL
acrylamide	NULL
gel	NULL
containing	NULL
2	NULL
%	NULL
glycerol	NULL
and	NULL
0.5	NULL
%	NULL
TBE	NULL
(	NULL
45	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
8.3	NULL
]	NULL
,	NULL
45	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
)	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
2.5	NULL
h	NULL
at	NULL
110	NULL
V.	NULL
Competition	NULL
experiments	NULL
were	NULL
performed	NULL
by	NULL
supplementing	NULL
the	NULL
reaction	NULL
mixture	NULL
with	NULL
20	NULL
ng	NULL
(	NULL
~200-fold	NULL
molar	NULL
excess	NULL
)	NULL
of	NULL
unlabeled	NULL
competitor	NULL
probe	NULL
.	NULL

For	NULL
the	NULL
supershift	NULL
experiments	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
mg	NULL
of	NULL
the	NULL
indicated	NULL
antibody	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotech-nology	NULL
)	NULL
,	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
and	NULL
binding	NULL
buffer	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
labeled	NULL
CD4-CRE	NULL
probe	NULL
was	NULL
added	NULL
,	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
before	NULL
separation	NULL
on	NULL
gel	NULL
.	NULL

Western	NULL
blot	NULL
.	NULL

HSB-2	NULL
or	NULL
HSB-2	NULL
cells	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
multiplicity	NULL
of	NULL
infection	NULL
,	NULL
0.1	NULL
)	NULL
for	NULL
either	NULL
48	NULL
or	NULL
72	NULL
h	NULL
were	NULL
lysed	NULL
in	NULL
Laemmli	NULL
SDS-PAGE	NULL
sample	NULL
buffer	NULL
.	NULL

Proteins	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cell	NULL
equivalent	NULL
)	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
an	NULL
SDS-10	NULL
%	NULL
acrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
onto	NULL
polyvinylidene	NULL
diflu-oride	NULL
membranes	NULL
.	NULL

Blots	NULL
were	NULL
probe	NULL
for	NULL
cither	NULL
total	NULL
CREB	NULL
using	NULL
rabbit	NULL
anti-CREB	NULL
antibodies	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
or	NULL
for	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
CREB	NULL
(	NULL
P-CREB	NULL
)	NULL
using	NULL
specific	NULL
antibodies	NULL
(	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
N.Y.	NULL
)	NULL
.	NULL

Alkaline	NULL
phosphatase-conjugated	NULL
goat	NULL
anti-rabbit	NULL
antibodies	NULL
were	NULL
used	NULL
as	NULL
secondary	NULL
antibodies	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
proteins	NULL
made	NULL
by	NULL
chemiluminescence	NULL
.	NULL

Quantification	NULL
of	NULL
CREB	NULL
and	NULL
P-CREB	NULL
protein	NULL
levels	NULL
was	NULL
performed	NULL
by	NULL
laser	NULL
densitometry	NULL
analysis	NULL
.	NULL

Immediate-early	NULL
genes	NULL
of	NULL
HHV-6	NULL
.	NULL

Plasmids	NULL
containing	NULL
open	NULL
reading	NULL
frames	NULL
(	NULL
ORFs	NULL
)	NULL
16/17	NULL
(	NULL
pIEGP2-3	NULL
'	NULL
)	NULL
and	NULL
ORFs	NULL
18/19	NULL
(	NULL
pIEG1-2	NULL
)	NULL
(	NULL
35	NULL
)	NULL
from	NULL
the	NULL
IE-B	NULL
region	NULL
and	NULL
a	NULL
plasmid	NULL
containing	NULL
ORF	NULL
86	NULL
(	NULL
pHV6U86	NULL
)	NULL
(	NULL
34	NULL
)	NULL
from	NULL
the	NULL
IE-A	NULL
region	NULL
were	NULL
generously	NULL
provided	NULL
by	NULL
John	NULL
Nicholas	NULL
.	NULL

pHV6U86	NULL
was	NULL
generated	NULL
by	NULL
PCR	NULL
using	NULL
the	NULL
following	NULL
primer	NULL
pair	NULL
:	NULL
sense	NULL
,	NULL
5'-GAAGGACTCGTCTCCGG-3	NULL
'	NULL
(	NULL
genome	NULL
coordinates	NULL
,	NULL
125787	NULL
to	NULL
125771	NULL
)	NULL
,	NULL
and	NULL
antisense	NULL
,	NULL
5'-GGGTGCTATCACA	NULL
TCAG-3	NULL
'	NULL
(	NULL
genome	NULL
coordinates	NULL
,	NULL
130936	NULL
to	NULL
130920	NULL
)	NULL
.	NULL

The	NULL
5.1-kbp	NULL
fragment	NULL
which	NULL
contains	NULL
the	NULL
entire	NULL
U86	NULL
ORF	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
pSK+	NULL
pBluescript	NULL
vector	NULL
.	NULL

The	NULL
expression	NULL
plasmid	NULL
pBC-ORF	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
Michelle	NULL
E.	NULL
D.	NULL
Martin	NULL
,	NULL
was	NULL
generated	NULL
by	NULL
PCR	NULL
using	NULL
the	NULL
following	NULL
primer	NULL
pair	NULL
:	NULL
sense	NULL
,	NULL
5'-ACATCTAGGTT	NULL
TCATCTAGC-3	NULL
'	NULL
(	NULL
genome	NULL
coordinates	NULL
,	NULL
133091	NULL
to	NULL
13072	NULL
)	NULL
,	NULL
and	NULL
antisense	NULL
,	NULL
5	NULL
``	NULL
-TT	NULL
AAACATGTGACATATAAC-3	NULL
'	NULL
(	NULL
genome	NULL
coordinates	NULL
,	NULL
135713	NULL
to	NULL
135694	NULL
)	NULL
.	NULL

The	NULL
2.6-kbp	NULL
PCR	NULL
fragment	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
entire	NULL
U89	NULL
ORF	NULL
,	NULL
was	NULL
cloned	NULL
into	NULL
pBC/CMV	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

RESULTS	NULL
Induction	NULL
of	NULL
cell	NULL
surface	NULL
CD4	NULL
expression	NULL
in	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
.	NULL

Previous	NULL
reports	NULL
have	NULL
shown	NULL
that	NULL
infection	NULL
of	NULL
mature	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
,	NULL
NK	NULL
cells	NULL
(	NULL
28	NULL
)	NULL
,	NULL
and	NULL
hematopoietic	NULL
cells	NULL
(	NULL
14	NULL
)	NULL
by	NULL
HHV-6	NULL
leads	NULL
to	NULL
CD4	NULL
gene	NULL
expression	NULL
.	NULL

Confirmation	NULL
of	NULL
these	NULL
results	NULL
has	NULL
now	NULL
been	NULL
extended	NULL
to	NULL
the	NULL
immature	NULL
,	NULL
voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
Isotype	NULL
control	NULL
_	NULL
Anti-CD4	NULL
2	NULL
2	NULL
h	NULL
2	NULL
to2	NULL
#	NULL
10°	NULL
a	NULL
!	NULL

**To	NULL
7	NULL
er	NULL
r	NULL
o	NULL
-	NULL
-	NULL
y	NULL
10	NULL
10	NULL
(	NULL
G	NULL
19°	NULL
10°	NULL
7	NULL
10°	NULL
10°	NULL
10+	NULL
v	NULL
w	NULL
e	NULL
#	NULL
-	NULL
6	NULL
24	NULL
a	NULL
(	NULL
“	NULL
23	NULL
``	NULL
B4	NULL
9,0	NULL
~	NULL
}	NULL
3	NULL
s	NULL
)	NULL
0-1	NULL
T.	NULL
°O	NULL
0	NULL
To	NULL
'	NULL
102	NULL
``	NULL
tos	NULL
507190	NULL
101	NULL
tne	NULL
4	NULL
10	NULL
10	NULL
10	NULL
10	NULL
10	NULL
HSB-2/HHV-6	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Cell	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
after	NULL
infection	NULL
of	NULL
HSB-2	NULL
cells	NULL
with	NULL
HHV-6	NULL
.	NULL

HSB-2	NULL
cells	NULL
(	NULL
CD4~	NULL
)	NULL
were	NULL
either	NULL
treated	NULL
with	NULL
mock-infected	NULL
culture	NULL
fluid	NULL
or	NULL
infected	NULL
with	NULL
HHV-6	NULL
(	NULL
GS	NULL
strain	NULL
)	NULL
.	NULL

When	NULL
signs	NULL
of	NULL
cytopathic	NULL
effect	NULL
were	NULL
observed	NULL
(	NULL
5	NULL
to	NULL
7	NULL
days	NULL
)	NULL
,	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
CD4	NULL
surface	NULL
expression	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
PE-labeled	NULL
anti-CD4	NULL
or	NULL
isotype-matched	NULL
control	NULL
antibody	NULL
.	NULL

Top	NULL
panels	NULL
represent	NULL
uninfected	NULL
cells	NULL
,	NULL
while	NULL
bottom	NULL
panels	NULL
depict	NULL
HHV-6-infected	NULL
cells	NULL
.	NULL

CD4~	NULL
T-cell	NULL
line	NULL
HSB-2	NULL
.	NULL

Ten	NULL
percent	NULL
of	NULL
7-day-old	NULL
productively	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
were	NULL
found	NULL
to	NULL
express	NULL
CD4	NULL
antigen	NULL
at	NULL
the	NULL
cell	NULL
surface	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

This	NULL
is	NULL
in	NULL
contrast	NULL
to	NULL
results	NULL
for	NULL
uninfected	NULL
cells	NULL
for	NULL
which	NULL
less	NULL
than	NULL
0.1	NULL
%	NULL
of	NULL
cells	NULL
were	NULL
found	NULL
positive	NULL
,	NULL
by	NULL
flow	NULL
cytometry	NULL
,	NULL
for	NULL
CD4	NULL
expression	NULL
.	NULL

Approximately	NULL
30	NULL
%	NULL
of	NULL
HSB-2	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HHV-6	NULL
as	NULL
determined	NULL
by	NULL
immunofluorescence	NULL
using	NULL
antibodies	NULL
specific	NULL
for	NULL
HHV-6	NULL
gp106	NULL
protein	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
HHV-6	NULL
.	NULL

CD4	NULL
gene	NULL
regulation	NULL
is	NULL
regulated	NULL
in	NULL
a	NULL
very	NULL
complex	NULL
manner	NULL
.	NULL

Several	NULL
genetic	NULL
elements	NULL
,	NULL
such	NULL
as	NULL
distal	NULL
and	NULL
proximal	NULL
enhancers	NULL
,	NULL
a	NULL
silencer	NULL
,	NULL
and	NULL
a	NULL
promoter	NULL
,	NULL
are	NULL
known	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
control	NULL
of	NULL
in	NULL
vivo	NULL
CD4	NULL
gene	NULL
expression	NULL
.	NULL

Our	NULL
present	NULL
work	NULL
focuses	NULL
mainly	NULL
on	NULL
the	NULL
interactions	NULL
between	NULL
HHV-6	NULL
and	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

To	NULL
study	NULL
the	NULL
effects	NULL
of	NULL
HHV-6	NULL
on	NULL
CD4	NULL
promoter	NULL
activity	NULL
,	NULL
we	NULL
cloned	NULL
,	NULL
upstream	NULL
of	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
,	NULL
the	NULL
1,076-bp	NULL
CD4	NULL
promoter	NULL
in	NULL
the	NULL
promoterless	NULL
pGL3basic	NULL
vector	NULL
to	NULL
create	NULL
the	NULL
-1076CD4p	NULL
plasmid	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
in	NULL
duplicate	NULL
either	NULL
with	NULL
the	NULL
pGL3basic	NULL
vector	NULL
or	NULL
with	NULL
the	NULL
full-length	NULL
CD4	NULL
promoter	NULL
and	NULL
subsequently	NULL
infected	NULL
with	NULL
HHV-6	NULL
.	NULL

Two	NULL
days	NULL
after	NULL
infection	NULL
,	NULL
luciferase	NULL
activity	NULL
was	NULL
monitored	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
HHV-6	NULL
can	NULL
minimally	NULL
activate	NULL
the	NULL
pGL3basic	NULL
vector	NULL
.	NULL

However	NULL
,	NULL
HHV-6	NULL
was	NULL
able	NULL
to	NULL
strongly	NULL
transactivate	NULL
the	NULL
full-length	NULL
CD4	NULL
promoter	NULL
with	NULL
greater	NULL
than	NULL
a	NULL
10-fold	NULL
increase	NULL
in	NULL
activity	NULL
when	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
pGL3basic	NULL
vector	NULL
.	NULL

CD4	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
-	NULL
8799	NULL
A	NULL
1500	NULL
&	NULL
3	NULL
6	NULL
i	NULL
1000	NULL
-	NULL
{	NULL
Mock	NULL
t	NULL
5	NULL
n	NULL
HHv-s	NULL
44	NULL
'	NULL
o	NULL
3	NULL
3	NULL
soo-3	NULL
c	NULL
P4	NULL
o-pGL3	NULL
~1076CD4p	NULL
-	NULL
-1076CD4p/PFA	NULL
Plasmid/Treatment	NULL
B	NULL
200	NULL
150	NULL
100	NULL
[	NULL
1	NULL
]	NULL
Mock	NULL
I	NULL
HHV-6	NULL
50	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
2	NULL
4	NULL
8	NULL
24	NULL
48	NULL
Time	NULL
(	NULL
hours	NULL
)	NULL
post	NULL
HHV-6	NULL
infection	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
HHV-6	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
control	NULL
(	NULL
pGL3	NULL
)	NULL
or	NULL
with	NULL
-1076CD4p	NULL
constructs	NULL
and	NULL
infected	NULL
with	NULL
HHV-6	NULL
or	NULL
treated	NULL
with	NULL
mock-infected	NULL
culture	NULL
supernatant	NULL
.	NULL

PFA	NULL
was	NULL
added	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
infection	NULL
,	NULL
and	NULL
PFA	NULL
was	NULL
kept	NULL
throughout	NULL
the	NULL
experiment	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
at	NULL
48	NULL
h	NULL
postinfection	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
(	NULL
mean	NULL
+	NULL
standard	NULL
deviation	NULL
)	NULL
,	NULL
expressed	NULL
as	NULL
relative	NULL
luciferase	NULL
activity	NULL
,	NULL
are	NULL
calculated	NULL
from	NULL
triplicate	NULL
cultures	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Kinetics	NULL
of	NULL
CD4	NULL
promoter	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
-1076CD4p	NULL
construct	NULL
and	NULL
treated	NULL
,	NULL
the	NULL
next	NULL
day	NULL
,	NULL
with	NULL
cither	NULL
mock-infected	NULL
fluid	NULL
or	NULL
with	NULL
HHV-6	NULL
.	NULL

At	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
,	NULL
cell	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
(	NULL
mean	NULL
+	NULL
standard	NULL
deviation	NULL
)	NULL
are	NULL
calculated	NULL
from	NULL
triplicate	NULL
cultures	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
previously	NULL
that	NULL
HHV-6	NULL
can	NULL
induce	NULL
cell	NULL
surface	NULL
CD4	NULL
expression	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
viral	NULL
DNA	NULL
polymerase	NULL
inhibitor	NULL
,	NULL
(	NULL
26	NULL
)	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
HHV-6	NULL
can	NULL
activate	NULL
the	NULL
CD4	NULL
promoter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PFA	NULL
,	NULL
HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
full-length	NULL
CD4	NULL
promoter	NULL
plasmid	NULL
and	NULL
infected	NULL
with	NULL
HHV-6	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PFA	NULL
.	NULL

Results	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
indicate	NULL
that	NULL
luciferase	NULL
activity	NULL
in	NULL
the	NULL
PFA-treated	NULL
group	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
untreated	NULL
,	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
an	NULL
immediate-early	NULL
or	NULL
early	NULL
gene	NULL
(	NULL
s	NULL
)	NULL
of	NULL
HHV-6	NULL
is	NULL
sufficient	NULL
for	NULL
CD4	NULL
promoter	NULL
transactivation	NULL
.	NULL

Effectiveness	NULL
of	NULL
PFA	NULL
treatment	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
HHV-6	NULL
glycoprotein	NULL
B	NULL
expression	NULL
,	NULL
a	NULL
late	NULL
viral	NULL
gene	NULL
product	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Kinetics	NULL
of	NULL
CD4	NULL
promoter	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

In	NULL
the	NULL
next	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
performed	NULL
kinetic	NULL
analyses	NULL
of	NULL
CD4	NULL
promoter	NULL
activation	NULL
by	NULL
HHV-6	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
full-length	NULL
CD4	NULL
promoter	NULL
and	NULL
infected	NULL
with	NULL
HHV-6	NULL
on	NULL
the	NULL
next	NULL
day	NULL
.	NULL

At	NULL
various	NULL
times	NULL
after	NULL
infection	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8800	NULL
FLAMAND	NULL
ET	NULL
AL	NULL
.	NULL

Luciferase	NULL
A	NULL
CD4	NULL
Promoter	NULL
-1076CD4p	NULL
«	NULL
618CDap	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-______	NULL
]	NULL
mepap	NULL
-	NULL
[	NULL
______	NULL
]	NULL
P	NULL
H10TeMSCD4p	NULL
--	NULL
-	NULL
___	NULL
]	NULL
nmscbap	NULL
+-	NULL
[	NULL
______	NULL
]	NULL
7	NULL
+21	NULL
Ms	NULL
crogy	NULL
AAATTGGGGCCGGCCCCAGCCCTA	NULL
AGGAGCCTTGCCATCGGGCTICCTGTCTCTCTTCATTIAAGCACGACTCTGCAG	NULL
B	NULL
-71M5	NULL
CD4p	NULL
1	NULL
-1076M5	NULL
CD4p	NULL
A-71-44	NULL
CD4p	NULL
4	NULL
-44	NULL
CD4p	NULL
4	NULL
-71	NULL
CD4p	NULL
--	NULL
--	NULL
333	NULL
CD4p	NULL
--	NULL
-618	NULL
CD4p	NULL
--	NULL
-1076	NULL
CD4p	NULL
--	NULL
-E-	NULL
U	NULL
T	NULL
U	NULL
T	NULL
t	NULL
U	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
25	NULL
30	NULL
Luciferase	NULL
Activity	NULL
(	NULL
fold	NULL
)	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
wild-type	NULL
(	NULL
-1076CD4p	NULL
)	NULL
and	NULL
mutant	NULL
CD4	NULL
promoter	NULL
luciferase	NULL
reporter	NULL
gene	NULL
constructs	NULL
.	NULL

The	NULL
cloning	NULL
plasmid	NULL
used	NULL
for	NULL
all	NULL
of	NULL
these	NULL
constructs	NULL
was	NULL
the	NULL
pGL3basic	NULL
vector	NULL
.	NULL

The	NULL
vertical	NULL
line	NULL
in	NULL
constructs	NULL
-1076M5CD4p	NULL
and	NULL
-71M5CD4p	NULL
represents	NULL
where	NULL
the	NULL
MS	NULL
mutation	NULL
was	NULL
in-troduced	NULL
.	NULL

The	NULL
MS	NULL
mutation	NULL
,	NULL
which	NULL
changes	NULL
the	NULL
putative	NULL
ATF/CRE	NULL
site	NULL
(	NULL
under-lined	NULL
)	NULL
of	NULL
the	NULL
wild-type	NULL
sequence	NULL
to	NULL
TTTAAATT	NULL
(	NULL
double	NULL
underline	NULL
)	NULL
,	NULL
is	NULL
shown	NULL
at	NULL
the	NULL
bottom	NULL
of	NULL
the	NULL
panel	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Identification	NULL
of	NULL
a	NULL
minimal	NULL
CD4	NULL
promoter	NULL
responsive	NULL
to	NULL
HHV-6	NULL
.	NULL

HSB-2	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
series	NULL
of	NULL
mutants	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
and	NULL
subsequently	NULL
infected	NULL
with	NULL
HHV-6	NULL
or	NULL
treated	NULL
with	NULL
mock-infected	NULL
culture	NULL
supernatant	NULL
(	NULL
mock	NULL
)	NULL
.	NULL

Forty-eight	NULL
hours	NULL
postinfection	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
,	NULL
from	NULL
triplicate	NULL
cultures	NULL
,	NULL
are	NULL
representative	NULL
of	NULL
five	NULL
experiments	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
after	NULL
normalization	NULL
with	NULL
values	NULL
from	NULL
uninfected	NULL
,	NULL
transfected	NULL
HSB-2	NULL
cells	NULL
.	NULL

2B	NULL
,	NULL
there	NULL
is	NULL
no	NULL
promoter	NULL
activity	NULL
during	NULL
the	NULL
first	NULL
8	NULL
h	NULL
postinfec-tion	NULL
.	NULL

However	NULL
,	NULL
at	NULL
both	NULL
24	NULL
and	NULL
48	NULL
h	NULL
postinfection	NULL
,	NULL
a	NULL
strong	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
was	NULL
detected	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
no	NULL
activity	NULL
was	NULL
recorded	NULL
during	NULL
the	NULL
initial	NULL
phases	NULL
of	NULL
infection	NULL
(	NULL
2	NULL
to	NULL
8	NULL
h	NULL
)	NULL
suggests	NULL
that	NULL
CD4	NULL
promoter	NULL
activation	NULL
by	NULL
HHV-6	NULL
is	NULL
not	NULL
simply	NULL
the	NULL
consequence	NULL
of	NULL
receptor-mediated	NULL
transcriptional	NULL
activation	NULL
.	NULL

In	NULL
support	NULL
of	NULL
such	NULL
hypothesis	NULL
is	NULL
the	NULL
fact	NULL
that	NULL
UV-irradiated	NULL
HHV-6	NULL
,	NULL
which	NULL
allows	NULL
binding	NULL
of	NULL
the	NULL
virus	NULL
to	NULL
its	NULL
receptor	NULL
but	NULL
prevents	NULL
transcription	NULL
of	NULL
viral	NULL
genes	NULL
,	NULL
failed	NULL
to	NULL
transactivate	NULL
the	NULL
CD4	NULL
promoter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
minimal	NULL
CD4	NULL
promoter	NULL
responsive	NULL
to	NULL
HHV-6	NULL
.	NULL

As	NULL
represented	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
eight	NULL
different	NULL
CD4	NULL
promoter	NULL
constructs	NULL
were	NULL
generated	NULL
.	NULL

These	NULL
range	NULL
from	NULL
a	NULL
full-length	NULL
CD4	NULL
promoter	NULL
(	NULL
-1076CD4p	NULL
)	NULL
to	NULL
a	NULL
CD4	NULL
promoter	NULL
containing	NULL
only	NULL
44	NULL
nucleotides	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
(	NULL
-44CD4p	NULL
)	NULL
.	NULL

Also	NULL
included	NULL
is	NULL
an	NULL
internal	NULL
deletion	NULL
construct	NULL
(	NULL
A-71-44CD4p	NULL
)	NULL
and	NULL
site-directed	NULL
mutant	NULL
promoters	NULL
(	NULL
-1076M5CD4p	NULL
and	NULL
=-71M5CD4p	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
in	NULL
the	NULL
first	NULL
series	NULL
of	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
that	NULL
J.	NULL
ViRoL	NULL
.	NULL

the	NULL
CD4	NULL
promoter	NULL
can	NULL
be	NULL
efficiently	NULL
transactivated	NULL
by	NULL
HHV-6	NULL
.	NULL

To	NULL
better	NULL
identify	NULL
which	NULL
region	NULL
(	NULL
s	NULL
)	NULL
of	NULL
the	NULL
promoter	NULL
is	NULL
responsive	NULL
to	NULL
HHV-6	NULL
,	NULL
we	NULL
tested	NULL
a	NULL
series	NULL
of	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
independently	NULL
transfected	NULL
into	NULL
HSB-2	NULL
cells	NULL
,	NULL
followed	NULL
by	NULL
infection	NULL
with	NULL
HHV-6	NULL
.	NULL

All	NULL
constructs	NULL
showed	NULL
similar	NULL
activity	NULL
under	NULL
basal	NULL
conditions	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
HHV-6	NULL
.	NULL

The	NULL
-1076CD4p	NULL
,	NULL
-618CD4p	NULL
,	NULL
-333CD4p	NULL
,	NULL
and	NULL
-71CD4p	NULL
constructs	NULL
were	NULL
equally	NULL
responsive	NULL
to	NULL
HHV-6	NULL
infection	NULL
,	NULL
as	NULL
evidenced	NULL
by	NULL
the	NULL
fold	NULL
induction	NULL
in	NULL
luciferase	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
removal	NULL
of	NULL
an	NULL
additional	NULL
27	NULL
nucleotides	NULL
from	NULL
the	NULL
-71CD4p	NULL
plasmid	NULL
,	NULL
to	NULL
create	NULL
the	NULL
-44CD4p	NULL
plasmid	NULL
,	NULL
was	NULL
found	NULL
to	NULL
significantly	NULL
impair	NULL
the	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
activate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
greater	NULL
than	NULL
fourfold	NULL
decrease	NULL
in	NULL
luciferase	NULL
activity	NULL
is	NULL
recorded	NULL
with	NULL
the	NULL
-44CD4p	NULL
plasmid	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
-71CD4p	NULL
vector	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
ATF/CRE	NULL
site	NULL
important	NULL
for	NULL
transactivation	NULL
by	NULL
HHV-6	NULL
.	NULL

The	NULL
region	NULL
located	NULL
between	NULL
-71	NULL
and	NULL
-44	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
is	NULL
important	NULL
for	NULL
HHV-6-mediated	NULL
transactivation	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
other	NULL
cis-acting	NULL
elements	NULL
play	NULL
a	NULL
role	NULL
in	NULL
HHV-6	NULL
transactivation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
construct	NULL
in	NULL
which	NULL
the	NULL
region	NULL
from	NULL
-71	NULL
to	NULL
-44	NULL
was	NULL
deleted	NULL
,	NULL
leaving	NULL
the	NULL
rest	NULL
of	NULL
the	NULL
promoter	NULL
intact	NULL
(	NULL
construct	NULL
A-71-44CD4p	NULL
,	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

This	NULL
construct	NULL
was	NULL
transfected	NULL
in	NULL
HSB-2	NULL
cells	NULL
and	NULL
tested	NULL
for	NULL
HHV-6	NULL
responsiveness	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
the	NULL
A-71-44CD4p	NULL
construct	NULL
responded	NULL
to	NULL
HHV-6	NULL
with	NULL
a	NULL
reduced	NULL
transactivation	NULL
ability	NULL
,	NULL
as	NULL
was	NULL
the	NULL
case	NULL
with	NULL
the	NULL
-44CD4p	NULL
construct	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
DNA	NULL
sequences	NULL
located	NULL
elsewhere	NULL
than	NULL
within	NULL
the	NULL
-71	NULL
to	NULL
-44	NULL
region	NULL
do	NULL
not	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
transactivate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Computer	NULL
analysis	NULL
of	NULL
the	NULL
-71	NULL
to	NULL
-44	NULL
region	NULL
reveals	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
putative	NULL
ATF/CRE	NULL
binding	NULL
site	NULL
.	NULL

The	NULL
region	NULL
from	NULL
-67	NULL
to	NULL
-62	NULL
contains	NULL
the	NULL
sequence	NULL
TGA	NULL
CGT	NULL
,	NULL
which	NULL
is	NULL
identical	NULL
to	NULL
six	NULL
of	NULL
the	NULL
eight	NULL
nucleotides	NULL
from	NULL
a	NULL
consensus	NULL
ATF/CRE	NULL
site	NULL
(	NULL
TGACGTCA	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
this	NULL
site	NULL
is	NULL
of	NULL
importance	NULL
for	NULL
HHV-6	NULL
transactivation	NULL
,	NULL
we	NULL
mutated	NULL
the	NULL
TGACGT	NULL
site	NULL
to	NULL
TTTAAA	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
this	NULL
site	NULL
was	NULL
performed	NULL
in	NULL
both	NULL
the	NULL
wild-type	NULL
CD4	NULL
promoter	NULL
(	NULL
-1076M5CD4p	NULL
)	NULL
and	NULL
in	NULL
the	NULL
minimal	NULL
-=71CD4p	NULL
(	NULL
-71M5CD4p	NULL
)	NULL
construct	NULL
.	NULL

Mutated	NULL
plasmids	NULL
were	NULL
transfected	NULL
in	NULL
parallel	NULL
with	NULL
the	NULL
wild-type	NULL
constructs	NULL
and	NULL
tested	NULL
for	NULL
responsiveness	NULL
to	NULL
HHV-6	NULL
.	NULL

The	NULL
results	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
indicate	NULL
that	NULL
mutation	NULL
of	NULL
the	NULL
putative	NULL
ATF/CRE	NULL
site	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
is	NULL
detrimental	NULL
for	NULL
HHV-6	NULL
transactivation	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
activation	NULL
are	NULL
similar	NULL
to	NULL
those	NULL
obtained	NULL
with	NULL
the	NULL
constructs	NULL
lacking	NULL
the	NULL
ATF/CRE	NULL
site	NULL
(	NULL
-44CD4p	NULL
and	NULL
A-71-44CD4p	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
putative	NULL
ATF/CRE	NULL
sites	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

We	NULL
demonstrated	NULL
that	NULL
the	NULL
putative	NULL
ATF/CRE	NULL
site	NULL
,	NULL
located	NULL
between	NULL
-71	NULL
and	NULL
-44	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
is	NULL
important	NULL
for	NULL
transactivation	NULL
by	NULL
HHV-6	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
-79	NULL
to	NULL
-52	NULL
region	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
both	NULL
uninfected	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
were	NULL
obtained	NULL
and	NULL
used	NULL
in	NULL
binding	NULL
assays	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
extracts	NULL
from	NULL
both	NULL
sources	NULL
efficiently	NULL
bind	NULL
the	NULL
CD4	NULL
oligonucleotide	NULL
,	NULL
with	NULL
no	NULL
apparent	NULL
differences	NULL
in	NULL
the	NULL
intensity	NULL
or	NULL
pattern	NULL
of	NULL
binding	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
homologous	NULL
competition	NULL
with	NULL
unlabeled	NULL
CD4	NULL
oligonucleotide	NULL
was	NULL
very	NULL
efficient	NULL
.	NULL

Equally	NULL
efficient	NULL
was	NULL
a	NULL
competition	NULL
between	NULL
the	NULL
CD4	NULL
oligonucleotide	NULL
and	NULL
an	NULL
oligonucleotide	NULL
containing	NULL
a	NULL
wild-type	NULL
CRE	NULL
site	NULL
.	NULL

However	NULL
,	NULL
no	NULL
competition	NULL
could	NULL
be	NULL
observed	NULL
with	NULL
an	NULL
oligonucleotide	NULL
having	NULL
a	NULL
mutated	NULL
CRE	NULL
(	NULL
M-CRE	NULL
)	NULL
consensus	NULL
se-quence	NULL
.	NULL

In	NULL
an	NULL
effort	NULL
to	NULL
better	NULL
characterize	NULL
the	NULL
protein	NULL
complex	NULL
binding	NULL
to	NULL
the	NULL
CD4	NULL
oligonucleotide	NULL
,	NULL
we	NULL
proceeded	NULL
to	NULL
perform	NULL
voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
A	NULL
>	NULL
Antibody	NULL
C	NULL
u	NULL
&	NULL
C	NULL
u	NULL
e	NULL
Competitor	NULL
03	NULL
(	NULL
4	NULL
?	NULL

45	NULL
”	NULL
6	NULL
?	NULL

a	NULL
?	NULL

”	NULL
$	NULL
1	NULL
Nuclear	NULL
Extract	NULL
HSB-2	NULL
HHV6-HSB-2	NULL
Supershift	NULL
-	NULL
>	NULL
sa	NULL
Shift	NULL
-	NULL
>	NULL
wee	NULL
BB	NULL
|	NULL
cy	NULL
WWL	NULL
@	NULL
Sn	NULL
B	NULL
[	NULL
]	NULL
Mock	NULL
EK	NULL
Forskolin	NULL
Luciferase	NULL
Activity	NULL
(	NULL
fold	NULL
)	NULL
to	NULL
1	NULL
pGL3Basic	NULL
-71	NULL
CD4p	NULL
-	NULL
-44	NULL
CD4p	NULL
-71M5	NULL
CD4p	NULL
&	NULL
£	NULL
5	NULL
8	NULL
M	NULL
gee	NULL
2	NULL
if	NULL
E	NULL
P-CREB	NULL
=	NULL
<	NULL
n	NULL
cee	NULL
cres	NULL
-	NULL
Q	NULL
P-CREB	NULL
1.0	NULL
3.0	NULL
3.1	NULL
CREB	NULL
10	NULL
17	NULL
14	NULL
P-CREB	NULL
CREB	NULL
1.0	NULL
18	NULL
22	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Binding	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
uninfected	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
were	NULL
obtained	NULL
and	NULL
subjected	NULL
to	NULL
gel-shift	NULL
assays	NULL
,	NULL
using	NULL
the	NULL
*°P-labeled	NULL
probe	NULL
spanning	NULL
the	NULL
-79	NULL
to	NULL
-52	NULL
region	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Competition	NULL
with	NULL
a	NULL
200-fold	NULL
excess	NULL
of	NULL
cold	NULL
CD4	NULL
probe	NULL
,	NULL
wild-type	NULL
ATF/CRE	NULL
,	NULL
and	NULL
mutated	NULL
ATF/CRE	NULL
sequence	NULL
was	NULL
performed	NULL
.	NULL

Incubation	NULL
of	NULL
extracts	NULL
with	NULL
antibodies	NULL
reacting	NULL
with	NULL
various	NULL
transcription	NULL
factors	NULL
was	NULL
also	NULL
included	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
forskolin	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
the	NULL
pGL3basic	NULL
,	NULL
-71CD4p	NULL
,	NULL
-44CD4p	NULL
,	NULL
or	NULL
-71M5CD4p	NULL
construct	NULL
and	NULL
treated	NULL
with	NULL
DMSO	NULL
(	NULL
mock	NULL
)	NULL
or	NULL
10	NULL
M	NULL
forskolin	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
,	NULL
obtained	NULL
from	NULL
triplicate	NULL
cultures	NULL
,	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Increased	NULL
CREB	NULL
phosphorylation	NULL
in	NULL
HHV-6-infected	NULL
cells	NULL
.	NULL

HSB-2	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
(	NULL
48	NULL
and	NULL
72	NULL
h	NULL
postinfection	NULL
)	NULL
were	NULL
lysed	NULL
in	NULL
Laemmli	NULL
buffer	NULL
and	NULL
analyzed	NULL
for	NULL
total	NULL
CREB	NULL
and	NULL
P-CREB	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
specific	NULL
antibodies	NULL
.	NULL

Ratios	NULL
of	NULL
P-CREB/	NULL
CREB	NULL
were	NULL
calculated	NULL
for	NULL
each	NULL
sample	NULL
following	NULL
densitometric	NULL
analysis	NULL
of	NULL
au-toradiograms	NULL
and	NULL
normalization	NULL
against	NULL
CREB	NULL
and	NULL
P-CREB	NULL
values	NULL
of	NULL
the	NULL
mock-infected	NULL
sample	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
.	NULL

CD4	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
-	NULL
8801	NULL
supershift	NULL
experiments	NULL
using	NULL
commercially	NULL
available	NULL
antibodies	NULL
that	NULL
react	NULL
against	NULL
known	NULL
transcription	NULL
factors	NULL
.	NULL

We	NULL
first	NULL
selected	NULL
antibodies	NULL
that	NULL
were	NULL
cross-reactive	NULL
against	NULL
several	NULL
proteins	NULL
known	NULL
to	NULL
bind	NULL
DNA	NULL
sequences	NULL
having	NULL
homologies	NULL
to	NULL
the	NULL
putative	NULL
ATF/CRE	NULL
site	NULL
found	NULL
within	NULL
the	NULL
CD4	NULL
oligonucleotide	NULL
.	NULL

The	NULL
antibodies	NULL
used	NULL
were	NULL
capable	NULL
of	NULL
binding	NULL
CREB-1/ATF-1/	NULL
CREM-1	NULL
,	NULL
CREB-2/ATF-4	NULL
,	NULL
c-Jun/AP-1/JunB/JunD	NULL
,	NULL
and	NULL
Ets-1/	NULL
Ets-2	NULL
as	NULL
negative	NULL
controls	NULL
.	NULL

When	NULL
used	NULL
in	NULL
the	NULL
binding	NULL
reactions	NULL
,	NULL
only	NULL
the	NULL
antibodies	NULL
reacting	NULL
with	NULL
CREB-1/ATF-1/CREM-1	NULL
caused	NULL
a	NULL
supershift	NULL
of	NULL
the	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

With	NULL
the	NULL
use	NULL
of	NULL
monospecific	NULL
antibodies	NULL
against	NULL
CREB-1	NULL
,	NULL
we	NULL
positively	NULL
identified	NULL
the	NULL
CREB-1	NULL
protein	NULL
as	NULL
one	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
as	NULL
witnessed	NULL
by	NULL
reduced	NULL
mobility	NULL
(	NULL
supershift	NULL
)	NULL
of	NULL
the	NULL
protein	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Antibodies	NULL
to	NULL
CREB-2	NULL
were	NULL
used	NULL
as	NULL
negative	NULL
controls	NULL
.	NULL

Antibodies	NULL
against	NULL
CREM-1	NULL
were	NULL
also	NULL
unreactive	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
forskolin	NULL
.	NULL

Transcriptional	NULL
activation	NULL
via	NULL
ATF/CRE	NULL
sites	NULL
is	NULL
often	NULL
regulated	NULL
through	NULL
the	NULL
action	NULL
of	NULL
protein	NULL
kinase	NULL
A	NULL
(	NULL
PKA	NULL
)	NULL
which	NULL
phosphorylates	NULL
and	NULL
thereby	NULL
activates	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
CREB	NULL
(	NULL
17	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Since	NULL
PKA	NULL
activity	NULL
is	NULL
influenced	NULL
by	NULL
levels	NULL
of	NULL
intracellular	NULL
cAMP	NULL
(	NULL
cAMP	NULL
;	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
an	NULL
agonist	NULL
such	NULL
as	NULL
forskolin	NULL
,	NULL
which	NULL
causes	NULL
an	NULL
increase	NULL
in	NULL
cAMP	NULL
,	NULL
,	NULL
can	NULL
activate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Transfected	NULL
HeLa	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
forskolin	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
indicate	NULL
that	NULL
the	NULL
promoterless	NULL
pGL3basic	NULL
and	NULL
-44CD4p	NULL
constructs	NULL
were	NULL
not	NULL
activated	NULL
by	NULL
DMSO	NULL
(	NULL
solvent	NULL
)	NULL
or	NULL
by	NULL
forskolin	NULL
.	NULL

However	NULL
,	NULL
the	NULL
-71CD4p	NULL
construct	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
ATF/	NULL
CRE	NULL
sequence	NULL
,	NULL
is	NULL
efficiently	NULL
activated	NULL
by	NULL
forskolin	NULL
(	NULL
fivefold	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
DMSO	NULL
(	NULL
mock	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
-71M5CD4p	NULL
construct	NULL
which	NULL
contains	NULL
a	NULL
mutated	NULL
ATF/CRE	NULL
consensus	NULL
site	NULL
was	NULL
not	NULL
responsive	NULL
to	NULL
forskolin	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
within	NULL
the	NULL
CD4	NULL
promoter	NULL
can	NULL
be	NULL
regulated	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
by	NULL
cAMP	NULL
and	NULL
PKA	NULL
.	NULL

Analysis	NULL
of	NULL
CREB	NULL
and	NULL
phosphorylated	NULL
CREB	NULL
in	NULL
HHV-6-infected	NULL
cells	NULL
.	NULL

Knowing	NULL
that	NULL
there	NULL
is	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
binding	NULL
pattern	NULL
or	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
proteins	NULL
bound	NULL
to	NULL
the	NULL
-79	NULL
to	NULL
-52	NULL
region	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
we	NULL
studied	NULL
,	NULL
by	NULL
Western	NULL
blot	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
prosphorylated	NULL
CREB	NULL
(	NULL
P-CREB	NULL
)	NULL
in	NULL
extracts	NULL
of	NULL
HSB-2	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
.	NULL

Forty-eight	NULL
and	NULL
72	NULL
h	NULL
after	NULL
infection	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
lysed	NULL
in	NULL
SDS-PAGE	NULL
buffer	NULL
and	NULL
proteins	NULL
from	NULL
2	NULL
X	NULL
10°	NULL
cell	NULL
equivalents	NULL
were	NULL
separated	NULL
by	NULL
gel	NULL
electrophoresis	NULL
.	NULL

After	NULL
transfer	NULL
onto	NULL
a	NULL
mem-brane	NULL
,	NULL
blots	NULL
were	NULL
probed	NULL
with	NULL
either	NULL
anti-CREB	NULL
or	NULL
anti-P-CREB	NULL
antibodies	NULL
.	NULL

Results	NULL
indicate	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
that	NULL
levels	NULL
of	NULL
P-CREB	NULL
in	NULL
the	NULL
infected	NULL
samples	NULL
are	NULL
twofold	NULL
higher	NULL
than	NULL
those	NULL
in	NULL
the	NULL
mock-infected	NULL
cells	NULL
when	NULL
compared	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
unphosphorylated	NULL
CREB	NULL
.	NULL

P-CREB	NULL
levels	NULL
of	NULL
expression	NULL
in	NULL
HHV-6-infected	NULL
cells	NULL
were	NULL
calculated	NULL
after	NULL
normalization	NULL
against	NULL
CREB	NULL
and	NULL
P-CREB	NULL
levels	NULL
of	NULL
expression	NULL
in	NULL
the	NULL
mock-infected	NULL
samples	NULL
.	NULL

Identification	NULL
of	NULL
HHV-6	NULL
ORFs	NULL
86	NULL
and	NULL
89	NULL
as	NULL
CD4	NULL
promoter	NULL
transactivators	NULL
.	NULL

From	NULL
our	NULL
kinetics	NULL
data	NULL
and	NULL
the	NULL
results	NULL
obtained	NULL
using	NULL
the	NULL
drug	NULL
PFA	NULL
,	NULL
we	NULL
deduced	NULL
that	NULL
virally	NULL
encoded	NULL
proteins	NULL
belonging	NULL
to	NULL
the	NULL
immediate-early	NULL
or	NULL
early	NULL
class	NULL
of	NULL
protein	NULL
were	NULL
involved	NULL
in	NULL
CD4	NULL
promoter	NULL
activation	NULL
.	NULL

In	NULL
an	NULL
effort	NULL
to	NULL
identify	NULL
such	NULL
proteins	NULL
,	NULL
we	NULL
tested	NULL
constructs	NULL
containing	NULL
ORFs	NULL
from	NULL
both	NULL
the	NULL
IE-A	NULL
and	NULL
IE-B	NULL
regions	NULL
of	NULL
HHV-6	NULL
.	NULL

The	NULL
plasmids	NULL
contained	NULL
U16/17	NULL
and	NULL
U18/19	NULL
from	NULL
the	NULL
IE-B	NULL
region	NULL
and	NULL
U86	NULL
and	NULL
US	NULL
$	NULL
from	NULL
the	NULL
IE-A	NULL
region	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
transactivator	NULL
U25	NULL
(	NULL
35	NULL
)	NULL
was	NULL
also	NULL
tested	NULL
.	NULL

These	NULL
plasmids	NULL
were	NULL
independently	NULL
cotransfected	NULL
into	NULL
HeLa	NULL
cells	NULL
with	NULL
the	NULL
-71CD4p	NULL
construct	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
chosen	NULL
for	NULL
their	NULL
much	NULL
higher	NULL
efficiency	NULL
of	NULL
transfection	NULL
(	NULL
15	NULL
to	NULL
20	NULL
%	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
following	NULL
transfection	NULL
with	NULL
pGreen	NULL
Lantern	NULL
8802	NULL
FLAMAND	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
10	NULL
4	NULL
€	NULL
+	NULL
2	NULL
2	NULL
64	NULL
3	NULL
)	NULL
<	NULL
2	NULL
ce	NULL
£	NULL
3	NULL
H0	NULL
27	NULL
o-peDNA3.1	NULL
UI§/U17	NULL
U18/U19	NULL
U25	NULL
U86	NULL
US	NULL
$	NULL
B	NULL
6	NULL
Luciferase	NULL
Activity	NULL
(	NULL
fold	NULL
)	NULL
to	NULL
1	NULL
-71CD4p	NULL
-71M5CDA4p	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Transactivation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
by	NULL
genes	NULL
of	NULL
HHV-6	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
either	NULL
the	NULL
control	NULL
vector	NULL
(	NULL
peDNA3.1	NULL
)	NULL
or	NULL
with	NULL
plasmids	NULL
encoding	NULL
HHV-6	NULL
genes	NULL
(	NULL
0.75	NULL
ug	NULL
each	NULL
)	NULL
along	NULL
with	NULL
the	NULL
-71CD4p	NULL
(	NULL
0.75	NULL
g	NULL
)	NULL
construct	NULL
.	NULL

Forty-eight	NULL
hours	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
fold	NULL
increase	NULL
in	NULL
luciferase	NULL
activity	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effects	NULL
of	NULL
ATF/CRE	NULL
mutation	NULL
of	NULL
transactivation	NULL
by	NULL
U86	NULL
and	NULL
U89	NULL
of	NULL
HHV-6	NULL
.	NULL

HeLa	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
either	NULL
the	NULL
pcDNA3.1	NULL
control	NULL
vector	NULL
or	NULL
the	NULL
U86	NULL
or	NULL
the	NULL
U89	NULL
construct	NULL
along	NULL
with	NULL
the	NULL
-71CD4p	NULL
or	NULL
the	NULL
-71M5CD4p	NULL
reporter	NULL
plasmid	NULL
.	NULL

Forty-cight	NULL
hours	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

The	NULL
fold	NULL
activation	NULL
of	NULL
pcDNA	NULL
,	NULL
U86	NULL
,	NULL
and	NULL
U89	NULL
is	NULL
represented	NULL
by	NULL
an	NULL
open	NULL
box	NULL
,	NULL
a	NULL
hatched	NULL
box	NULL
,	NULL
and	NULL
a	NULL
filled	NULL
box	NULL
,	NULL
respectively	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

plasmid	NULL
)	NULL
than	NULL
HSB-2	NULL
cells	NULL
(	NULL
<	NULL
1	NULL
%	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
vector	NULL
peDNA3.1	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

Forty-eight	NULL
hours	NULL
posttransfection	NULL
,	NULL
cells	NULL
were	NULL
lysed	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
U16/	NULL
U17	NULL
,	NULL
U18/U19	NULL
,	NULL
or	NULL
the	NULL
peDNA3.1	NULL
control	NULL
vector	NULL
showed	NULL
comparable	NULL
low	NULL
levels	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
plasmid	NULL
containing	NULL
U25	NULL
showed	NULL
limited	NULL
transactivation	NULL
,	NULL
with	NULL
a	NULL
2.5-fold	NULL
increase	NULL
in	NULL
reporter	NULL
activity	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
U86	NULL
and	NULL
U89	NULL
constructs	NULL
were	NULL
capable	NULL
of	NULL
transactivating	NULL
the	NULL
-71CD4p	NULL
promoter	NULL
construct	NULL
significantly	NULL
,	NULL
with	NULL
a	NULL
seven-	NULL
to	NULL
ninefold	NULL
increase	NULL
in	NULL
activity	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
U8S6	NULL
and	NULL
U89	NULL
transactivators	NULL
were	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
ATF/CRE	NULL
site	NULL
to	NULL
mediate	NULL
their	NULL
effects	NULL
,	NULL
we	NULL
carried	NULL
out	NULL
similar	NULL
experiments	NULL
using	NULL
the	NULL
-71M5CD4p	NULL
construct	NULL
as	NULL
the	NULL
reporter	NULL
plasmid	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
the	NULL
U86	NULL
and	NULL
U8S9	NULL
constructs	NULL
were	NULL
equally	NULL
efficient	NULL
in	NULL
transactivating	NULL
both	NULL
the	NULL
-71CD4p	NULL
and	NULL
the	NULL
-71M5CD4p	NULL
plas-mids	NULL
,	NULL
suggesting	NULL
an	NULL
ATF/CRE-independent	NULL
mode	NULL
of	NULL
action	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

The	NULL
peDNA3.1	NULL
vector	NULL
was	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
for	NULL
the	NULL
experiment	NULL
and	NULL
for	NULL
the	NULL
normalization	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

DISCUSSION	NULL
T-cell	NULL
precursors	NULL
migrating	NULL
out	NULL
of	NULL
the	NULL
bone	NULL
marrow	NULL
and	NULL
arriving	NULL
in	NULL
the	NULL
thymus	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
CD4	NULL
(	NULL
CD4®CD8~	NULL
)	NULL
(	NULL
51	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
eventually	NULL
lose	NULL
CD4	NULL
expression	NULL
and	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
double-negative	NULL
(	NULL
CD4	NULL
CD8	NULL
)	NULL
thymocytes	NULL
.	NULL

During	NULL
subsequent	NULL
maturation	NULL
steps	NULL
,	NULL
the	NULL
CD4	NULL
,	NULL
CD8	NULL
,	NULL
and	NULL
TCR	NULL
genes	NULL
are	NULL
upregulated	NULL
,	NULL
forming	NULL
a	NULL
population	NULL
of	NULL
double-positive	NULL
(	NULL
CD4*CD8+*	NULL
)	NULL
cells	NULL
.	NULL

Last	NULL
,	NULL
following	NULL
positive	NULL
and/or	NULL
negative	NULL
selection	NULL
,	NULL
survivor	NULL
cells	NULL
lose	NULL
expression	NULL
of	NULL
CD4	NULL
or	NULL
CD8	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
mature	NULL
CD4	NULL
*~CD8~	NULL
or	NULL
CD4~-CD8*	NULL
T-cell	NULL
phenotype	NULL
as	NULL
seen	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
is	NULL
very	NULL
complex	NULL
and	NULL
relies	NULL
on	NULL
the	NULL
participation	NULL
of	NULL
several	NULL
cis-acting	NULL
elements	NULL
,	NULL
such	NULL
as	NULL
promoter	NULL
,	NULL
enhancer	NULL
,	NULL
and	NULL
silencer	NULL
.	NULL

The	NULL
original	NULL
description	NULL
of	NULL
the	NULL
human	NULL
CD4	NULL
promoter	NULL
indicates	NULL
a	NULL
lack	NULL
of	NULL
both	NULL
TATA	NULL
and	NULL
CAAT	NULL
boxes	NULL
,	NULL
no	NULL
defined	NULL
initiator	NULL
sequence	NULL
,	NULL
and	NULL
few	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Binding	NULL
sites	NULL
for	NULL
and	NULL
physical	NULL
binding	NULL
of	NULL
Ets	NULL
and	NULL
Myb	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
CD4	NULL
promoter	NULL
have	NULL
been	NULL
observed	NULL
(	NULL
40	NULL
,	NULL
45	NULL
)	NULL
.	NULL

A	NULL
minimal	NULL
human	NULL
CD4	NULL
promoter	NULL
(	NULL
nucleotides	NULL
located	NULL
at	NULL
-40	NULL
to	NULL
+16	NULL
relative	NULL
to	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
)	NULL
with	NULL
reduced	NULL
activity	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
full-length	NULL
promoter	NULL
was	NULL
identified	NULL
(	NULL
40	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
additional	NULL
cis-acting	NULL
elements	NULL
upstream	NULL
of	NULL
this	NULL
minimal	NULL
promoter	NULL
are	NULL
needed	NULL
for	NULL
full	NULL
activity	NULL
.	NULL

We	NULL
began	NULL
to	NULL
study	NULL
the	NULL
human	NULL
CD4	NULL
promoter	NULL
during	NULL
an	NULL
attempt	NULL
to	NULL
identify	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
HHV-6	NULL
induces	NULL
CD4	NULL
gene	NULL
expression	NULL
in	NULL
CD4~	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
mature	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
and	NULL
a	NULL
hematopoietic	NULL
progenitor	NULL
cell	NULL
line	NULL
.	NULL

In	NULL
general	NULL
,	NULL
once	NULL
a	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
has	NULL
reached	NULL
maturity	NULL
,	NULL
it	NULL
never	NULL
expresses	NULL
the	NULL
CD4	NULL
antigen	NULL
.	NULL

In	NULL
such	NULL
cells	NULL
,	NULL
CD4	NULL
gene	NULL
transcription	NULL
is	NULL
shut	NULL
off	NULL
through	NULL
the	NULL
action	NULL
of	NULL
the	NULL
CD4	NULL
silencer	NULL
located	NULL
within	NULL
the	NULL
first	NULL
intron	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
(	NULL
42	NULL
,	NULL
44	NULL
)	NULL
.	NULL

The	NULL
mode	NULL
of	NULL
action	NULL
of	NULL
the	NULL
silencer	NULL
is	NULL
not	NULL
completely	NULL
understood	NULL
.	NULL

The	NULL
silencer	NULL
is	NULL
not	NULL
,	NULL
however	NULL
,	NULL
the	NULL
only	NULL
element	NULL
capable	NULL
of	NULL
exerting	NULL
a	NULL
negative	NULL
regulatory	NULL
action	NULL
on	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

If	NULL
such	NULL
was	NULL
the	NULL
case	NULL
,	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
silencer	NULL
se-quences	NULL
,	NULL
would	NULL
be	NULL
active	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
both	NULL
the	NULL
human	NULL
and	NULL
mouse	NULL
CD4	NULL
promoters	NULL
are	NULL
highly	NULL
active	NULL
in	NULL
CD4*	NULL
cells	NULL
and	NULL
much	NULL
less	NULL
in	NULL
CD4~	NULL
cells	NULL
(	NULL
40	NULL
,	NULL
45	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
CD4	NULL
promoter	NULL
is	NULL
tissue	NULL
specific	NULL
.	NULL

One	NULL
hypothesis	NULL
is	NULL
that	NULL
promoter	NULL
activity	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
may	NULL
be	NULL
influenced	NULL
by	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
key	NULL
transcription	NULL
factors	NULL
needed	NULL
to	NULL
fully	NULL
activate	NULL
the	NULL
promoter	NULL
.	NULL

When	NULL
the	NULL
effects	NULL
of	NULL
HHV-6	NULL
infection	NULL
on	NULL
CD4	NULL
promoter	NULL
activity	NULL
were	NULL
tested	NULL
,	NULL
we	NULL
noticed	NULL
that	NULL
this	NULL
virus	NULL
can	NULL
very	NULL
efficiently	NULL
transactivate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

CD4	NULL
promoter	NULL
activation	NULL
in	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
(	NULL
a	NULL
CD4_	NULL
immature	NULL
T-cell	NULL
line	NULL
)	NULL
was	NULL
paralleled	NULL
by	NULL
cell	NULL
surface	NULL
induction	NULL
of	NULL
the	NULL
CD4	NULL
antigen	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
,	NULL
at	NULL
any	NULL
given	NULL
time	NULL
,	NULL
we	NULL
do	NULL
not	NULL
detect	NULL
more	NULL
than	NULL
10	NULL
to	NULL
15	NULL
%	NULL
of	NULL
HSB-2	NULL
cells	NULL
expressing	NULL
surface	NULL
CD4	NULL
,	NULL
although	NULL
more	NULL
than	NULL
30	NULL
%	NULL
are	NULL
infected	NULL
with	NULL
HHV-6	NULL
as	NULL
determined	NULL
by	NULL
immunofluorescence	NULL
assay	NULL
,	NULL
suggests	NULL
that	NULL
CD4	NULL
induction	NULL
may	NULL
not	NULL
be	NULL
permanent	NULL
.	NULL

This	NULL
is	NULL
most	NULL
likely	NULL
the	NULL
result	NULL
of	NULL
asynchronous	NULL
lytic	NULL
replication	NULL
and	NULL
cytopathic	NULL
effects	NULL
.	NULL

Using	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
a	NULL
minimal	NULL
promoter	NULL
(	NULL
from	NULL
-71	NULL
to	NULL
+21	NULL
)	NULL
responsive	NULL
to	NULL
HHV-6	NULL
.	NULL

This	NULL
result	NULL
suggests	NULL
that	NULL
cis	NULL
elements	NULL
upstream	NULL
of	NULL
this	NULL
region	NULL
are	NULL
not	NULL
involved	NULL
in	NULL
HHV-6	NULL
activation	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Removal	NULL
of	NULL
an	NULL
additional	NULL
27	NULL
nucleotides	NULL
greatly	NULL
affected	NULL
the	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
activate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
region	NULL
from	NULL
-71	NULL
to	NULL
-44	NULL
revealed	NULL
a	NULL
partial	NULL
ATF/CRE	NULL
site	NULL
(	NULL
TGACGTTT	NULL
)	NULL
homologous	NULL
to	NULL
six	NULL
of	NULL
the	NULL
eight	NULL
nucleotides	NULL
of	NULL
voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
the	NULL
wild-type	NULL
consensus	NULL
sequence	NULL
(	NULL
TGACGTCA	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
ATF/CRE	NULL
site	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
to	NULL
TTTAAATT	NULL
or	NULL
deletion	NULL
of	NULL
the	NULL
-71	NULL
-44	NULL
region	NULL
from	NULL
the	NULL
full-length	NULL
promoter	NULL
was	NULL
also	NULL
found	NULL
to	NULL
impair	NULL
the	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
transactivate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

ATF/CRE	NULL
sites	NULL
are	NULL
present	NULL
and	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
many	NULL
cellular	NULL
and	NULL
viral	NULL
promoters	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
HHV-6	NULL
DNA	NULL
polymerase	NULL
promoter	NULL
contains	NULL
a	NULL
single	NULL
ATF/	NULL
CRE	NULL
site	NULL
located	NULL
at	NULL
the	NULL
-70	NULL
region	NULL
that	NULL
is	NULL
critical	NULL
for	NULL
promoter	NULL
activity	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Removal	NULL
or	NULL
mutation	NULL
of	NULL
the	NULL
ATF/CRE	NULL
site	NULL
eliminated	NULL
the	NULL
ability	NULL
of	NULL
HHV-6	NULL
to	NULL
activate	NULL
its	NULL
own	NULL
polymerase	NULL
promoter	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
HHV-6	NULL
was	NULL
shown	NULL
to	NULL
transactivate	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
Zebra	NULL
promoter	NULL
through	NULL
a	NULL
single	NULL
ATF/CRE	NULL
site	NULL
(	NULL
TGACATCA	NULL
)	NULL
located	NULL
in	NULL
the	NULL
-67	NULL
to	NULL
-60	NULL
region	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
ATF/CRE	NULL
site	NULL
can	NULL
bind	NULL
numerous	NULL
transcription	NULL
factors	NULL
belonging	NULL
to	NULL
the	NULL
bZIP	NULL
leucine	NULL
zipper	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
including	NULL
ATF/CREB/CREM	NULL
,	NULL
Fos/Jun	NULL
,	NULL
and	NULL
C/EBP	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
,	NULL
and	NULL
those	NULL
of	NULL
Agulnik	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
and	NULL
Flamand	NULL
and	NULL
Menezes	NULL
(	NULL
12	NULL
)	NULL
,	NULL
indicate	NULL
that	NULL
constitutively	NULL
expressed	NULL
proteins	NULL
bind	NULL
to	NULL
the	NULL
ATF/CRE	NULL
sites	NULL
.	NULL

To	NULL
better	NULL
characterize	NULL
the	NULL
interaction	NULL
between	NULL
HHV-6	NULL
and	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
we	NULL
studied	NULL
,	NULL
using	NULL
gel	NULL
shift	NULL
assays	NULL
,	NULL
the	NULL
binding	NULL
patterns	NULL
of	NULL
proteins	NULL
from	NULL
uninfected	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
binding	NULL
intensities	NULL
or	NULL
binding	NULL
patterns	NULL
between	NULL
extracts	NULL
from	NULL
uninfected	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
could	NULL
be	NULL
de-tected	NULL
,	NULL
suggesting	NULL
that	NULL
viral	NULL
transactivators	NULL
do	NULL
not	NULL
bind	NULL
DNA	NULL
directly	NULL
or	NULL
that	NULL
they	NULL
are	NULL
too	NULL
limited	NULL
in	NULL
amount	NULL
for	NULL
detection	NULL
.	NULL

In	NULL
order	NULL
to	NULL
identify	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
bound	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
of	NULL
the	NULL
CD4	NULL
promoter	NULL
within	NULL
cell	NULL
extracts	NULL
,	NULL
we	NULL
made	NULL
use	NULL
of	NULL
antibodies	NULL
directed	NULL
against	NULL
several	NULL
transcription	NULL
factors	NULL
known	NULL
for	NULL
their	NULL
binding	NULL
to	NULL
ATF/CRE	NULL
sites	NULL
.	NULL

Only	NULL
one	NULL
of	NULL
these	NULL
antibodies	NULL
was	NULL
found	NULL
to	NULL
be	NULL
reactive	NULL
for	NULL
the	NULL
complex	NULL
bound	NULL
to	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
identifying	NULL
at	NULL
least	NULL
one	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
as	NULL
CREB-1	NULL
.	NULL

These	NULL
results	NULL
were	NULL
further	NULL
confirmed	NULL
by	NULL
using	NULL
recombinant	NULL
CREB-1	NULL
protein	NULL
,	NULL
which	NULL
could	NULL
efficiently	NULL
bind	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
within	NULL
the	NULL
CD4	NULL
promoter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Viral	NULL
transactivators	NULL
may	NULL
interact	NULL
with	NULL
basal	NULL
transcription	NULL
units	NULL
and	NULL
adjacent	NULL
transcription	NULL
factors	NULL
,	NULL
bridging	NULL
them	NULL
together	NULL
to	NULL
allow	NULL
efficient	NULL
transcription	NULL
to	NULL
occur	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
some	NULL
of	NULL
the	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
ATF/CRE	NULL
site	NULL
,	NULL
such	NULL
as	NULL
CREB	NULL
,	NULL
efficiently	NULL
bind	NULL
DNA	NULL
but	NULL
are	NULL
transcriptionally	NULL
inactive	NULL
until	NULL
they	NULL
become	NULL
phosphorylated	NULL
(	NULL
17	NULL
,	NULL
22	NULL
)	NULL
.	NULL

To	NULL
help	NULL
explain	NULL
efficient	NULL
CD4	NULL
promoter	NULL
transactivation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
constant	NULL
levels	NULL
of	NULL
CREB-1	NULL
protein	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
levels	NULL
of	NULL
active	NULL
CREB	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
phosphorylated	NULL
CREB-1	NULL
in	NULL
extracts	NULL
from	NULL
uninfected	NULL
and	NULL
HHV-6-infected	NULL
HSB-2	NULL
cells	NULL
.	NULL

Using	NULL
specific	NULL
monoclonal	NULL
antibodies	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
show	NULL
increased	NULL
levels	NULL
of	NULL
the	NULL
phosphorylated	NULL
form	NULL
of	NULL
CREB	NULL
in	NULL
HHV-6-infected	NULL
cell	NULL
extracts	NULL
when	NULL
compared	NULL
to	NULL
those	NULL
of	NULL
uninfected	NULL
HSB-2	NULL
cells	NULL
.	NULL

Viral	NULL
transactivators	NULL
may	NULL
therefore	NULL
directly	NULL
,	NULL
or	NULL
indirectly	NULL
through	NULL
activation	NULL
of	NULL
cellular	NULL
kinases	NULL
,	NULL
promote	NULL
transcription	NULL
through	NULL
the	NULL
phosphorylation	NULL
of	NULL
key	NULL
regulatory	NULL
transcription	NULL
factors	NULL
.	NULL

Kinetics	NULL
analyses	NULL
suggest	NULL
that	NULL
direct	NULL
transduction	NULL
of	NULL
signals	NULL
resulting	NULL
from	NULL
the	NULL
interactions	NULL
of	NULL
HHV-6	NULL
with	NULL
its	NULL
cellular	NULL
re-ceptor	NULL
(	NULL
s	NULL
)	NULL
is	NULL
not	NULL
responsible	NULL
for	NULL
CD4	NULL
promoter	NULL
activation	NULL
.	NULL

More	NULL
than	NULL
8	NULL
h	NULL
of	NULL
infection	NULL
were	NULL
needed	NULL
for	NULL
CD4	NULL
promoter	NULL
activa-tion	NULL
,	NULL
indicating	NULL
,	NULL
in	NULL
all	NULL
likelihood	NULL
,	NULL
that	NULL
cellular	NULL
and/or	NULL
viral	NULL
proteins	NULL
outside	NULL
the	NULL
signaling	NULL
cascade	NULL
are	NULL
needed	NULL
.	NULL

Supporting	NULL
this	NULL
hypothesis	NULL
is	NULL
the	NULL
observation	NULL
that	NULL
UV-irradiated	NULL
HHV-6	NULL
,	NULL
which	NULL
can	NULL
still	NULL
bind	NULL
to	NULL
cells	NULL
but	NULL
can	NULL
not	NULL
transcribe	NULL
any	NULL
of	NULL
its	NULL
genes	NULL
,	NULL
does	NULL
not	NULL
activate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

To	NULL
better	NULL
characterize	NULL
the	NULL
gene	NULL
(	NULL
s	NULL
)	NULL
of	NULL
HHV-6	NULL
involved	NULL
in	NULL
CD4	NULL
promoter	NULL
acti-vation	NULL
,	NULL
we	NULL
made	NULL
use	NULL
of	NULL
the	NULL
drug	NULL
PFA	NULL
which	NULL
restricts	NULL
gene	NULL
expression	NULL
of	NULL
the	NULL
immediate-early	NULL
and	NULL
early	NULL
classes	NULL
of	NULL
genes	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
PFA	NULL
treatment	NULL
of	NULL
cells	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
ability	NULL
CD4	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
-	NULL
8803	NULL
of	NULL
HHV-6	NULL
to	NULL
activate	NULL
the	NULL
CD4	NULL
promoter	NULL
suggested	NULL
that	NULL
immediate-early	NULL
or	NULL
early	NULL
genes	NULL
were	NULL
involved	NULL
in	NULL
promoter	NULL
activation	NULL
.	NULL

The	NULL
HHV-6	NULL
genome	NULL
,	NULL
which	NULL
is	NULL
essentially	NULL
collinear	NULL
with	NULL
that	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
(	NULL
HMCV	NULL
)	NULL
(	NULL
16	NULL
,	NULL
23	NULL
,	NULL
32	NULL
)	NULL
,	NULL
contains	NULL
a	NULL
long	NULL
(	NULL
141	NULL
kbp	NULL
)	NULL
unique	NULL
coding	NULL
region	NULL
flanked	NULL
by	NULL
two	NULL
directly	NULL
repeated	NULL
terminal	NULL
sequences	NULL
of	NULL
approximately	NULL
8	NULL
kbp	NULL
each	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
unique	NULL
segment	NULL
,	NULL
two	NULL
loci	NULL
encoding	NULL
potential	NULL
immediate-early	NULL
genes	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

ORFs	NULL
16	NULL
to	NULL
19	NULL
of	NULL
the	NULL
immediate-early	NULL
region	NULL
B	NULL
are	NULL
homologous	NULL
to	NULL
UL36	NULL
to	NULL
UL38	NULL
of	NULL
HCMV	NULL
(	NULL
16	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Although	NULL
these	NULL
gene	NULL
segments	NULL
were	NULL
found	NULL
capable	NULL
of	NULL
transactivating	NULL
the	NULL
HIV	NULL
LTR	NULL
(	NULL
35	NULL
)	NULL
none	NULL
of	NULL
these	NULL
ORFs	NULL
was	NULL
able	NULL
to	NULL
transactivate	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

Region	NULL
A	NULL
,	NULL
the	NULL
second	NULL
HHV-6	NULL
immediate-early	NULL
locus	NULL
contains	NULL
U86	NULL
and	NULL
U89	NULL
,	NULL
which	NULL
are	NULL
positional	NULL
homologs	NULL
of	NULL
HCMV	NULL
IE2	NULL
and	NULL
IE1	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
cotransfection	NULL
experiments	NULL
,	NULL
U89	NULL
was	NULL
shown	NULL
capable	NULL
of	NULL
transactivating	NULL
the	NULL
HIV	NULL
LTR	NULL
(	NULL
30	NULL
)	NULL
.	NULL

When	NULL
we	NULL
tested	NULL
U86	NULL
and	NULL
U89	NULL
,	NULL
both	NULL
of	NULL
these	NULL
genes	NULL
were	NULL
found	NULL
to	NULL
be	NULL
capable	NULL
of	NULL
activating	NULL
the	NULL
CD4	NULL
promoter	NULL
.	NULL

U86	NULL
has	NULL
the	NULL
capacity	NULL
to	NULL
code	NULL
for	NULL
a	NULL
152-kDa	NULL
protein	NULL
whose	NULL
carboxy-terminal	NULL
half	NULL
has	NULL
homology	NULL
with	NULL
IE2	NULL
(	NULL
UL122	NULL
)	NULL
of	NULL
HCMV	NULL
(	NULL
16	NULL
)	NULL
.	NULL

U89	NULL
does	NULL
not	NULL
share	NULL
sequence	NULL
homology	NULL
with	NULL
any	NULL
HCMV	NULL
proteins	NULL
although	NULL
a	NULL
homologous	NULL
gene	NULL
is	NULL
observed	NULL
in	NULL
the	NULL
more	NULL
closely	NULL
related	NULL
HHV-7	NULL
(	NULL
33	NULL
)	NULL
.	NULL

U89	NULL
was	NULL
capable	NULL
of	NULL
transactivating	NULL
several	NULL
promoters	NULL
,	NULL
including	NULL
those	NULL
having	NULL
ATF	NULL
sites	NULL
such	NULL
as	NULL
the	NULL
E4	NULL
early	NULL
promoter	NULL
of	NULL
adenovirus	NULL
(	NULL
30	NULL
)	NULL
.	NULL

However	NULL
,	NULL
as	NULL
is	NULL
the	NULL
case	NULL
for	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
transactivation	NULL
of	NULL
the	NULL
E4	NULL
promoter	NULL
by	NULL
U89	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
ATF/CRE	NULL
consensus	NULL
sequence	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
by	NULL
U8S9	NULL
of	NULL
HHV-6	NULL
was	NULL
found	NULL
to	NULL
be	NULL
impaired	NULL
if	NULL
the	NULL
NFB	NULL
,	NULL
TATA	NULL
box	NULL
,	NULL
or	NULL
SP1	NULL
site	NULL
was	NULL
mutated	NULL
(	NULL
30	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
U89	NULL
and	NULL
perhaps	NULL
U86	NULL
act	NULL
as	NULL
transcriptional	NULL
enhancers	NULL
through	NULL
activation	NULL
or	NULL
recruitment	NULL
of	NULL
transcriptional	NULL
unit	NULL
complexes	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
multiple	NULL
distinct	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
U89	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
this	NULL
protein	NULL
does	NULL
not	NULL
bind	NULL
a	NULL
specific	NULL
DNA	NULL
consensus	NULL
sequence	NULL
but	NULL
rather	NULL
interacts	NULL
with	NULL
regulatory	NULL
proteins	NULL
common	NULL
to	NULL
many	NULL
transcriptional	NULL
units	NULL
.	NULL

HHV-6	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
the	NULL
transactivation	NULL
of	NULL
several	NULL
viral	NULL
promoters	NULL
,	NULL
including	NULL
those	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
12	NULL
)	NULL
and	NULL
HIV	NULL
(	NULL
8	NULL
,	NULL
15	NULL
,	NULL
19	NULL
,	NULL
50	NULL
)	NULL
.	NULL

The	NULL
present	NULL
study	NULL
indicates	NULL
that	NULL
HHV-6	NULL
can	NULL
also	NULL
efficiently	NULL
transactivate	NULL
the	NULL
human	NULL
CD4	NULL
promoter	NULL
.	NULL

A	NULL
previously	NULL
unrecognized	NULL
ATF/CRE	NULL
site	NULL
within	NULL
the	NULL
CD4	NULL
promoter	NULL
,	NULL
capable	NULL
of	NULL
binding	NULL
CREB-1	NULL
,	NULL
is	NULL
important	NULL
for	NULL
promoter	NULL
transactivation	NULL
by	NULL
HHV-6	NULL
.	NULL

Whether	NULL
CD4	NULL
gene	NULL
activation	NULL
and	NULL
de	NULL
novo	NULL
CD4	NULL
protein	NULL
expression	NULL
play	NULL
a	NULL
role	NULL
in	NULL
HHV-6	NULL
or	NULL
HIV	NULL
pathogenesis	NULL
is	NULL
unclear	NULL
.	NULL

CD4	NULL
gene	NULL
activation	NULL
could	NULL
simply	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
HHV-6	NULL
immediate-early	NULL
and/or	NULL
early	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
the	NULL
promiscuity	NULL
of	NULL
CRE	NULL
elements	NULL
in	NULL
viral	NULL
and	NULL
cellular	NULL
promoters	NULL
may	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
several	NULL
genes	NULL
sharing	NULL
such	NULL
common	NULL
regulatory	NULL
elements	NULL
.	NULL

The	NULL
HHV-6	NULL
TATA-less	NULL
DNA	NULL
polymerase	NULL
promoter	NULL
is	NULL
mainly	NULL
controlled	NULL
by	NULL
a	NULL
CRE	NULL
element	NULL
(	NULL
1	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
for	NULL
efficient	NULL
replication	NULL
HHV-6	NULL
must	NULL
have	NULL
evolved	NULL
mechanisms	NULL
capable	NULL
of	NULL
activating	NULL
transcription	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
CREB	NULL
,	NULL
involved	NULL
in	NULL
CRE-mediated	NULL
promoter	NULL
activation	NULL
.	NULL

Overall	NULL
,	NULL
our	NULL
results	NULL
provide	NULL
a	NULL
better	NULL
understanding	NULL
of	NULL
HHV-6	NULL
's	NULL
biology	NULL
and	NULL
give	NULL
new	NULL
insights	NULL
into	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
human	NULL
CD4	NULL
promoter	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
Throughout	NULL
these	NULL
studies	NULL
,	NULL
Louis	NULL
Flamand	NULL
was	NULL
supported	NULL
by	NULL
subsequent	NULL
Fellowships	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
and	NULL
from	NULL
the	NULL
National	NULL
Health	NULL
Research	NULL
and	NULL
Development	NULL
Program	NULL
of	NULL
Canada	NULL
.	NULL

LF	NULL
.	NULL

currently	NULL
holds	NULL
a	NULL
Scholarship	NULL
from	NULL
the	NULL
Fonds	NULL
de	NULL
la	NULL
Recherche	NULL
en	NULL
Santé	NULL
au	NULL
Québec	NULL
.	NULL

This	NULL
project	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Canada	NULL
to	NULL
LF	NULL
.	NULL

and	NULL
by	NULL
an	NULL
RO3	NULL
(	NULL
AI41854-02	NULL
)	NULL
grant	NULL
from	NULL
the	NULL
NIH	NULL
to	NULL
M.S.R	NULL
.	NULL

8804	NULL
FLAMAND	NULL
ET	NULL
AL	NULL
.	NULL

We	NULL
thank	NULL
Paolo	NULL
Lusso	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
John	NULL
Nicholas	NULL
and	NULL
Michelle	NULL
E.	NULL
D.	NULL
Martin	NULL
for	NULL
providing	NULL
HHV-6	NULL
plas-mids	NULL
.	NULL

REFERENCES	NULL
.	NULL

Agulnick	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
J.	NULL
R.	NULL
Thompson	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Ricciardi	NULL
.	NULL

1994	NULL
.	NULL

An	NULL
ATF/CREB	NULL
site	NULL
is	NULL
the	NULL
major	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
human	NULL
herpesvirus	NULL
6	NULL
DNA	NULL
polymerase	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:2970-2977.	NULL
.	NULL

Becker	NULL
,	NULL
W.	NULL
B.	NULL
,	NULL
S.	NULL
Engelbrecht	NULL
,	NULL
M.	NULL
L.	NULL
Becker	NULL
,	NULL
C.	NULL
Pick	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Robson	NULL
,	NULL
L.	NULL
Wood	NULL
,	NULL
and	NULL
P.	NULL
Jacobs	NULL
.	NULL

1988	NULL
.	NULL

Isolation	NULL
of	NULL
a	NULL
new	NULL
human	NULL
herpesvirus	NULL
producing	NULL
a	NULL
lytic	NULL
infection	NULL
of	NULL
helper	NULL
(	NULL
CD4	NULL
)	NULL
T-lymphocytes	NULL
in	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
cultures-another	NULL
cause	NULL
of	NULL
acquired	NULL
immunodeficiency	NULL
?	NULL

S.	NULL
Afr	NULL
.	NULL

Med	NULL
.	NULL

J	NULL
.	NULL

74:610-614.	NULL
.	NULL

Blue	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
J.	NULL
F.	NULL
Daley	NULL
,	NULL
H.	NULL
Levine	NULL
,	NULL
K.	NULL
A.	NULL
Craig	NULL
,	NULL
and	NULL
S.	NULL
F.	NULL
Schlossman	NULL
.	NULL

1986	NULL
.	NULL

Biosynthesis	NULL
and	NULL
surface	NULL
expression	NULL
of	NULL
T8	NULL
by	NULL
peripheral	NULL
blood	NULL
T4+	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

137:1202-1207.	NULL
.	NULL

Blum	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
G.	NULL
T.	NULL
Wong	NULL
,	NULL
K.	NULL
M.	NULL
Higgins	NULL
,	NULL
M.	NULL
J.	NULL
Sunshine	NULL
,	NULL
and	NULL
E.	NULL
Lacy	NULL
.	NULL

1993	NULL
.	NULL

Reconstitution	NULL
of	NULL
the	NULL
subclass-specific	NULL
expression	NULL
of	NULL
CD4	NULL
in	NULL
thymocytes	NULL
and	NULL
peripheral	NULL
T	NULL
cells	NULL
of	NULL
transgenic	NULL
mice	NULL
:	NULL
identification	NULL
of	NULL
a	NULL
human	NULL
CD4	NULL
enhancer	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:1343-1358.	NULL
.	NULL

Cammarota	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Scheirle	NULL
,	NULL
B.	NULL
Takacs	NULL
,	NULL
D.	NULL
M.	NULL
Doran	NULL
,	NULL
R.	NULL
Knorr	NULL
,	NULL
W.	NULL
Ban	NULL
nwarth	NULL
,	NULL
J.	NULL
Guardiola	NULL
,	NULL
and	NULL
F.	NULL
Sinigaglia	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
CD4	NULL
binding	NULL
site	NULL
on	NULL
the	NULL
beta	NULL
2	NULL
domain	NULL
of	NULL
HLA-DR	NULL
molecules	NULL
.	NULL

Nature	NULL
356:799-801	NULL
.	NULL

5a.Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcrip-	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21.	NULL
tion	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489.	NULL
.	NULL

Donda	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Schulz	NULL
,	NULL
K.	NULL
Burki	NULL
,	NULL
G.	NULL
De	NULL
Libero	NULL
,	NULL
and	NULL
Y.	NULL
Uematsu	NULL
.	NULL

1996	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
CD4	NULL
silencer	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

26:493-500.	NULL
.	NULL

Doyle	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Strominger	NULL
.	NULL

1987	NULL
.	NULL

Interaction	NULL
between	NULL
CD4	NULL
and	NULL
class	NULL
II	NULL
MHC	NULL
molecules	NULL
mediates	NULL
cell	NULL
adhesion	NULL
.	NULL

Nature	NULL
330:256-259.	NULL
.	NULL

Ensoli	NULL
,	NULL
B.	NULL
,	NULL
P.	NULL
Lusso	NULL
,	NULL
F.	NULL
Schachter	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
J.	NULL
Rappaport	NULL
,	NULL
F.	NULL
Negro	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1989	NULL
.	NULL

Human	NULL
herpes	NULL
virus-6	NULL
increases	NULL
HIV-1	NULL
expression	NULL
in	NULL
co-infected	NULL
T	NULL
cells	NULL
via	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
HIV-1	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:3019-3027.	NULL
.	NULL

Flamand	NULL
,	NULL
L.	NULL
,	NULL
R.	NULL
W.	NULL
Crowley	NULL
,	NULL
P.	NULL
Lusso	NULL
,	NULL
S.	NULL
Colombini-Hatch	NULL
,	NULL
D.	NULL
M.	NULL
Margolis	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
CD8+	NULL
T	NULL
lymphocytes	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
turns	NULL
on	NULL
CD4	NULL
gene	NULL
expression	NULL
:	NULL
implications	NULL
for	NULL
HIV	NULL
pathogenesis	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:3111-3116	NULL
.	NULL

Flamand	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
Gosselin	NULL
,	NULL
M.	NULL
D'Addario	NULL
,	NULL
J.	NULL
Hiscott	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
J.	NULL
Menezes	NULL
.	NULL

1991	NULL
.	NULL

Human	NULL
herpesvirus	NULL
6	NULL
induces	NULL
interleukin-1B	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
but	NULL
not	NULL
interleukin-6	NULL
,	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
cultures	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5105-5110	NULL
.	NULL

Flamand	NULL
,	NULL
L.	NULL
,	NULL
J.	NULL
Gosselin	NULL
,	NULL
I.	NULL
Stefanescu	NULL
,	NULL
D.	NULL
Ablashi	NULL
,	NULL
and	NULL
J.	NULL
Menezes	NULL
.	NULL

1995	NULL
.	NULL

Immunosuppressive	NULL
effect	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
on	NULL
T-cell	NULL
functions	NULL
:	NULL
suppression	NULL
of	NULL
interleukin-2	NULL
synthesis	NULL
and	NULL
cell	NULL
proliferation	NULL
.	NULL

Blood	NULL
85:1263-1271	NULL
.	NULL

Flamand	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
J.	NULL
Menezes	NULL
.	NULL

1996	NULL
.	NULL

Cyclic	NULL
AMP-responsive	NULL
element-depen-dent	NULL
activation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
ZEBRA	NULL
promoter	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:1784-1791	NULL
.	NULL

Fleury	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Lamarre	NULL
,	NULL
S.	NULL
Meloche	NULL
,	NULL
S.	NULL
E.	NULL
Ryu	NULL
,	NULL
C.	NULL
Cantin	NULL
,	NULL
W.	NULL
A.	NULL
Hendrickson	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Sekaly	NULL
.	NULL

1991	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
the	NULL
interaction	NULL
between	NULL
CD4	NULL
and	NULL
class	NULL
II	NULL
MHC	NULL
:	NULL
class	NULL
II	NULL
antigens	NULL
contact	NULL
CD4	NULL
on	NULL
a	NULL
surface	NULL
opposite	NULL
the	NULL
gp120-binding	NULL
site	NULL
.	NULL

Cell	NULL
66:1037-1049	NULL
.	NULL

Furlini	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Vignoli	NULL
,	NULL
E.	NULL
Ramazzotti	NULL
,	NULL
M.	NULL
C.	NULL
Re	NULL
,	NULL
G.	NULL
Visani	NULL
,	NULL
and	NULL
M.	NULL
LaPlaca	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
concurrent	NULL
human	NULL
herpesvirus-6	NULL
infection	NULL
renders	NULL
two	NULL
human	NULL
hematopoietic	NULL
progenitor	NULL
(	NULL
TF-1	NULL
and	NULL
KG-1	NULL
)	NULL
cell	NULL
lines	NULL
susceptible	NULL
to	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type-1	NULL
.	NULL

Blood	NULL
87:4737-4745	NULL
.	NULL

Geng	NULL
,	NULL
Y.	NULL
Q.	NULL
,	NULL
B.	NULL
Chandran	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
C.	NULL
Wood	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
herpesvirus	NULL
6	NULL
gene	NULL
segment	NULL
that	NULL
transacti-vates	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:1564-1570	NULL
.	NULL

Gompels	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
,	NULL
J.	NULL
Nicholas	NULL
,	NULL
G.	NULL
Lawrence	NULL
,	NULL
M.	NULL
Jones	NULL
,	NULL
B.	NULL
J.	NULL
Thomson	NULL
,	NULL
M.	NULL
E.	NULL
Martin	NULL
,	NULL
S.	NULL
Efstathiou	NULL
,	NULL
M.	NULL
Craxton	NULL
,	NULL
and	NULL
H.	NULL
A.	NULL
Macaulay	NULL
.	NULL

1995	NULL
.	NULL

The	NULL
DNA	NULL
sequence	NULL
of	NULL
human	NULL
herpesvirus-6	NULL
:	NULL
structure	NULL
,	NULL
coding	NULL
content	NULL
,	NULL
and	NULL
genome	NULL
evolution	NULL
.	NULL

Virology	NULL
209:29-51	NULL
.	NULL

Gonzalez	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1989	NULL
.	NULL

Cyclic	NULL
AMP	NULL
stimulates	NULL
soma-tostatin	NULL
gene	NULL
transcription	NULL
by	NULL
phosphorylation	NULL
of	NULL
CREB	NULL
at	NULL
serine	NULL
133	NULL
.	NULL

Cell	NULL
59:675-680	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
M.	NULL
J.	NULL
Parmely	NULL
,	NULL
and	NULL
B.	NULL
Chandran	NULL
.	NULL

1993	NULL
.	NULL

Human	NULL
herpesvirus	NULL
6	NULL
inhibits	NULL
the	NULL
proliferative	NULL
responses	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

167:1274-1280	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
C.	NULL
Wood	NULL
,	NULL
and	NULL
N.	NULL
Balachandran	NULL
.	NULL

1989	NULL
.	NULL

Transactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
promoter	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:970-973	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
,	NULL
C.	NULL
Wood	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
and	NULL
N.	NULL
Balachandran	NULL
.	NULL

1991	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
promoter	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
(	NULL
HHV-6	NULL
)	NULL
strains	NULL
GS	NULL
and	NULL
Z-29	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
and	NULL
identification	NULL
of	NULL
transactivating	NULL
HHV-6	NULL
(	NULL
GS	NULL
)	NULL
gene	NULL
fragments	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:2895-2902	NULL
.	NULL

Konig	NULL
,	NULL
R.	NULL
,	NULL
L.	NULL
Y.	NULL
Huang	NULL
,	NULL
and	NULL
R.	NULL
N.	NULL
Germain	NULL
.	NULL

1992	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
interaction	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

J.	NULL
ViRoL	NULL
.	NULL

with	NULL
CD4	NULL
mediated	NULL
by	NULL
a	NULL
region	NULL
analogous	NULL
to	NULL
the	NULL
MHC	NULL
class	NULL
I	NULL
binding	NULL
site	NULL
for	NULL
CD8	NULL
.	NULL

Nature	NULL
356:796-798	NULL
.	NULL

Lamph	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
V.	NULL
J.	NULL
Dwarki	NULL
,	NULL
R.	NULL
Ofir	NULL
,	NULL
M.	NULL
Montminy	NULL
,	NULL
and	NULL
I.	NULL
M.	NULL
Verma	NULL
.	NULL

1990	NULL
.	NULL

Negative	NULL
and	NULL
positive	NULL
regulation	NULL
by	NULL
transcription	NULL
factor	NULL
cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
is	NULL
modulated	NULL
by	NULL
phosphorylation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87:4320-4324	NULL
.	NULL

Lawrence	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
M.	NULL
Chee	NULL
,	NULL
M.	NULL
A.	NULL
Craxton	NULL
,	NULL
U	NULL
.	NULL

A.	NULL
Gompels	NULL
,	NULL
R.	NULL
W.	NULL
Honess	NULL
,	NULL
and	NULL
B.	NULL
G.	NULL
Barrell	NULL
.	NULL

1990	NULL
.	NULL

Human	NULL
herpesvirus	NULL
6	NULL
is	NULL
closely	NULL
related	NULL
to	NULL
human	NULL
cytomegalovirus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:287-299	NULL
.	NULL

Littman	NULL
,	NULL
D.	NULL
R.	NULL
1987	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
the	NULL
CD4	NULL
and	NULL
CD8	NULL
genes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

5561-584.	NULL
.	NULL

Lopez	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
Pellett	NULL
,	NULL
J.	NULL
Stewart	NULL
,	NULL
C.	NULL
Goldsmith	NULL
,	NULL
K.	NULL
Sanderlin	NULL
,	NULL
J	NULL
.	NULL

Black	NULL
,	NULL
D.	NULL
Warfield	NULL
,	NULL
and	NULL
P.	NULL
Feorino	NULL
.	NULL

1988	NULL
.	NULL

Characteristics	NULL
of	NULL
human	NULL
herpesvirus-6	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

157:1271-1273	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
A	NULL
.	NULL

De	NULL
Maria	NULL
,	NULL
M.	NULL
Malnati	NULL
,	NULL
F.	NULL
Lori	NULL
,	NULL
S.	NULL
E.	NULL
DeRocco	NULL
,	NULL
M.	NULL
Baseler	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
of	NULL
CD4	NULL
and	NULL
susceptibility	NULL
to	NULL
HIV-1	NULL
infection	NULL
in	NULL
human	NULL
CD8+	NULL
T	NULL
lymphocytes	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

Nature	NULL
349:533-535	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
B.	NULL
Ensoli	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
E.	NULL
Tschachler	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1989	NULL
.	NULL

Productive	NULL
dual	NULL
infection	NULL
of	NULL
human	NULL
CD4+	NULL
T	NULL
lymphocytes	NULL
by	NULL
HIV-1	NULL
and	NULL
HHV-6	NULL
.	NULL

Nature	NULL
337:370-373	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
S.	NULL
Malnati	NULL
,	NULL
A.	NULL
Garzino-Demo	NULL
,	NULL
R.	NULL
W.	NULL
Crowley	NULL
,	NULL
E.	NULL
O	NULL
.	NULL

Long	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1993	NULL
.	NULL

Infection	NULL
of	NULL
natural	NULL
killer	NULL
cells	NULL
by	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

Nature	NULL
362:458-462	NULL
.	NULL

Lusso	NULL
,	NULL
P.	NULL
,	NULL
P.	NULL
D.	NULL
Markham	NULL
,	NULL
E.	NULL
Tschachler	NULL
,	NULL
F.	NULL
di	NULL
Marzo	NULL
Veronese	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
D.	NULL
V.	NULL
Ablashi	NULL
,	NULL
S.	NULL
Pahwa	NULL
,	NULL
K.	NULL
Krohn	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1988	NULL
.	NULL

In	NULL
vitro	NULL
cellular	NULL
tropism	NULL
of	NULL
human	NULL
B-lymphotropic	NULL
virus	NULL
(	NULL
human	NULL
herpesvirus-6	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

167:1659-1670	NULL
.	NULL

Martin	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
J.	NULL
Nicholas	NULL
,	NULL
B.	NULL
J.	NULL
Thomson	NULL
,	NULL
C.	NULL
Newman	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Honess	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
transactivating	NULL
function	NULL
mapping	NULL
to	NULL
the	NULL
putative	NULL
immediate-early	NULL
locus	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5381-5390	NULL
.	NULL

Meyer	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
and	NULL
J.	NULL
F.	NULL
Habener	NULL
.	NULL

1993	NULL
.	NULL

Cyclic	NULL
adenosine	NULL
3',5'-monophos-phate	NULL
response	NULL
element	NULL
binding	NULL
protein	NULL
(	NULL
CREB	NULL
)	NULL
and	NULL
related	NULL
transcription-activating	NULL
deoxyribonucleic	NULL
acid-binding	NULL
proteins	NULL
.	NULL

Endocr	NULL
.	NULL

Rev	NULL
.	NULL

14:269-290	NULL
.	NULL

Neipel	NULL
,	NULL
F.	NULL
,	NULL
K.	NULL
Ellinger	NULL
,	NULL
and	NULL
B.	NULL
Fleckenstein	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
unique	NULL
region	NULL
of	NULL
the	NULL
human	NULL
herpesvirus	NULL
6	NULL
genome	NULL
is	NULL
essentially	NULL
collinear	NULL
with	NULL
the	NULL
UL	NULL
segment	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

72:2293-2297	NULL
.	NULL

Nicholas	NULL
,	NULL
J	NULL
.	NULL

1996	NULL
.	NULL

Determination	NULL
and	NULL
analysis	NULL
of	NULL
the	NULL
complete	NULL
nucleotide	NULL
sequence	NULL
of	NULL
human	NULL
herpesvirus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:5975-5989	NULL
.	NULL

Nicholas	NULL
,	NULL
J	NULL
.	NULL

1994	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
analysis	NULL
of	NULL
a	NULL
21-kbp	NULL
region	NULL
of	NULL
the	NULL
genome	NULL
of	NULL
human	NULL
herpesvirus-6	NULL
containing	NULL
homologues	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
major	NULL
immediate-early	NULL
and	NULL
replication	NULL
genes	NULL
.	NULL

Virology	NULL
204:738-750	NULL
.	NULL

Nicholas	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Martin	NULL
.	NULL

1994	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
analysis	NULL
of	NULL
a	NULL
38.5-kilobase-pair	NULL
region	NULL
of	NULL
the	NULL
genome	NULL
of	NULL
human	NULL
herpesvirus	NULL
6	NULL
encoding	NULL
human	NULL
cytomegalovirus	NULL
immediate-early	NULL
gene	NULL
homologs	NULL
and	NULL
transactivating	NULL
functions	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:597-610	NULL
.	NULL

Parnes	NULL
,	NULL
J.	NULL
R.	NULL
1989	NULL
.	NULL

Molecular	NULL
biology	NULL
and	NULL
function	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
.	NULL

Adv	NULL
.	NULL

Immunol	NULL
.	NULL

44:265-311	NULL
.	NULL

Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
J.	NULL
D.	NULL
Marth	NULL
,	NULL
S.	NULL
F.	NULL
Ziegler	NULL
,	NULL
A.	NULL
M.	NULL
Garvin	NULL
,	NULL
S.	NULL
Pawar	NULL
,	NULL
M.	NULL
P.	NULL
Cooke	NULL
,	NULL
and	NULL
K.	NULL
M.	NULL
Abraham	NULL
.	NULL

1989	NULL
.	NULL

Specialized	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
proto-oncogenes	NULL
in	NULL
hematopoietic	NULL
cells	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
948:245-262	NULL
.	NULL

Richardson	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
Kahn	NULL
,	NULL
E.	NULL
J.	NULL
Lovett	NULL
,	NULL
and	NULL
J.	NULL
Hudson	NULL
.	NULL

1986	NULL
.	NULL

Effect	NULL
of	NULL
an	NULL
inhibitor	NULL
of	NULL
DNA	NULL
methylation	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

I	NULL
.	NULL

5-Azacytidine	NULL
induces	NULL
T4	NULL
expression	NULL
on	NULL
T8+	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

137:35-39	NULL
.	NULL

Rudd	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
J.	NULL
M.	NULL
Trevillyan	NULL
,	NULL
J.	NULL
D.	NULL
Dasgupta	NULL
,	NULL
L.	NULL
L.	NULL
Wong	NULL
,	NULL
and	NULL
S.	NULL
F.	NULL
Schlossman	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
CD4	NULL
receptor	NULL
is	NULL
complexed	NULL
in	NULL
detergent	NULL
lysates	NULL
to	NULL
a	NULL
protein-tyrosine	NULL
kinase	NULL
(	NULL
pp38	NULL
)	NULL
from	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:5190-5194	NULL
.	NULL

Salmon	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Giovane	NULL
,	NULL
B.	NULL
Wasylyk	NULL
,	NULL
and	NULL
D.	NULL
Klatzmann	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
human	NULL
CD4	NULL
gene	NULL
promoter	NULL
:	NULL
transcription	NULL
from	NULL
the	NULL
CD4	NULL
gene	NULL
core	NULL
promoter	NULL
is	NULL
tissue-specific	NULL
and	NULL
is	NULL
activated	NULL
by	NULL
Ets	NULL
proteins	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7739-7743	NULL
.	NULL

Sawada	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Littman	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
T-cell-specific	NULL
enhancer	NULL
adjacent	NULL
to	NULL
the	NULL
murine	NULL
CD4	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11:5506-5515	NULL
.	NULL

Sawada	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
D.	NULL
Scarborough	NULL
,	NULL
N.	NULL
Killeen	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Littman	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
lineage-specific	NULL
transcriptional	NULL
silencer	NULL
regulates	NULL
CD4	NULL
gene	NULL
expression	NULL
during	NULL
T	NULL
lymphocyte	NULL
development	NULL
.	NULL

Cell	NULL
77:917-929	NULL
.	NULL

Shaw	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
K.	NULL
E.	NULL
Amrein	NULL
,	NULL
C.	NULL
Hammond	NULL
,	NULL
D.	NULL
F.	NULL
Stern	NULL
,	NULL
B.	NULL
M.	NULL
Sefton	NULL
,	NULL
and	NULL
J.	NULL
K.	NULL
Rose	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Ick	NULL
tyrosine	NULL
protein	NULL
kinase	NULL
interacts	NULL
with	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
CD4	NULL
glycoprotein	NULL
through	NULL
its	NULL
unique	NULL
amino-terminal	NULL
domain	NULL
.	NULL

Cell	NULL
59:627-636	NULL
.	NULL

Siu	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
L.	NULL
Wurster	NULL
,	NULL
D.	NULL
D.	NULL
Duncan	NULL
,	NULL
T.	NULL
M.	NULL
Soliman	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Hedrick	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
transcriptional	NULL
silencer	NULL
controls	NULL
the	NULL
developmental	NULL
expression	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

13:3570-3579	NULL
.	NULL

Siu	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
L.	NULL
Wurster	NULL
,	NULL
J.	NULL
S.	NULL
Lipsick	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Hedrick	NULL
.	NULL

1992	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
CD4	NULL
gene	NULL
requires	NULL
a	NULL
Myb	NULL
transcription	NULL
factor	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:1592-1604	NULL
.	NULL

Swain	NULL
,	NULL
S.	NULL
L.	NULL
1983	NULL
.	NULL

T	NULL
cell	NULL
subsets	NULL
and	NULL
the	NULL
recognition	NULL
of	NULL
MHC	NULL
class	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

74:129-142	NULL
.	NULL

Takahashi	NULL
,	NULL
K.	NULL
,	NULL
S.	NULL
Sonoda	NULL
,	NULL
K.	NULL
Higashi	NULL
,	NULL
T.	NULL
Kondo	NULL
,	NULL
H.	NULL
Takahashi	NULL
,	NULL
M.	NULL
Takahashi	NULL
,	NULL
and	NULL
K.	NULL
Yamanishi	NULL
.	NULL

1989	NULL
.	NULL

Predominant	NULL
CD4	NULL
T-lymphocyte	NULL
tropism	NULL
of	NULL
human	NULL
herpesvirus	NULL
6-related	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3161-3163.	NULL
voL	NULL
.	NULL

72	NULL
,	NULL
1998	NULL
48	NULL
.	NULL

Turner	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
M.	NULL
H.	NULL
Brodsky	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Irving	NULL
,	NULL
S.	NULL
D.	NULL
Levin	NULL
,	NULL
R.	NULL
M.	NULL
Perlmutter	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Littman	NULL
.	NULL

1990	NULL
.	NULL

Interaction	NULL
of	NULL
the	NULL
unique	NULL
N-terminal	NULL
region	NULL
of	NULL
tyrosine	NULL
kinase	NULL
p56	NULL
``	NULL
**	NULL
with	NULL
cytoplasmic	NULL
domains	NULL
of	NULL
CD4	NULL
and	NULL
CD8	NULL
is	NULL
mediated	NULL
by	NULL
cysteine	NULL
motifs	NULL
.	NULL

Cell	NULL
60:755-765	NULL
.	NULL

49	NULL
.	NULL

Veillette	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
A.	NULL
Bookman	NULL
,	NULL
E.	NULL
M.	NULL
Horak	NULL
,	NULL
and	NULL
J	NULL
.	NULL

B.	NULL
Bolen	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
CD4	NULL
and	NULL
CD8	NULL
T	NULL
cell	NULL
surface	NULL
antigens	NULL
are	NULL
associated	NULL
with	NULL
the	NULL
internal	NULL
membrane	NULL
tyrosine-protein	NULL
kinase	NULL
p56	NULL
``	NULL
.	NULL

Cell	NULL
55:301-308	NULL
.	NULL

50	NULL
.	NULL

Wang	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Jones	NULL
,	NULL
M.	NULL
Norcross	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
and	NULL
A.	NULL
Razzaque	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
a	NULL
human	NULL
herpesvirus	NULL
6	NULL
gene	NULL
segment	NULL
51	NULL
.	NULL

52	NULL
.	NULL

CD4	NULL
PROMOTER	NULL
ACTIVATION	NULL
BY	NULL
HHV-6	NULL
-	NULL
8805	NULL
capable	NULL
of	NULL
transactivating	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
an	NULL
Sp1	NULL
binding	NULL
site-dependent	NULL
manner	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:1706-1713	NULL
.	NULL

Wu	NULL
,	NULL
L.	NULL
,	NULL
R.	NULL
Scollay	NULL
,	NULL
M.	NULL
Egerton	NULL
,	NULL
M.	NULL
Pearse	NULL
,	NULL
G.	NULL
J.	NULL
Spangrude	NULL
,	NULL
and	NULL
K.	NULL
Short-man	NULL
.	NULL

1991	NULL
.	NULL

CD4	NULL
expressed	NULL
on	NULL
earliest	NULL
T-lineage	NULL
precursor	NULL
cells	NULL
in	NULL
the	NULL
adult	NULL
murine	NULL
thymus	NULL
.	NULL

Nature	NULL
349:71-74	NULL
.	NULL

Wurster	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
G.	NULL
Siu	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Hedrick	NULL
.	NULL

1994	NULL
.	NULL

Elf-1	NULL
binds	NULL
to	NULL
a	NULL
critical	NULL
element	NULL
in	NULL
a	NULL
second	NULL
CD4	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:6452-6463	NULL
.	NULL

